Combined RTK and SUMO inhibition for cancer therapy
The combination of RTK and SUMOylation inhibitors addresses the challenge of secondary resistance in cancer treatment by enhancing the sensitivity of cancer cells to RTK inhibitors, effectively treating malignant tumors by targeting and reversing resistance.
Patent Information
- Application Number
- PCT/US2024/031089
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-26
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-05
AI Technical Summary
Current RTK inhibitors face challenges with secondary resistance in cancer treatment due to adaptive reprogramming of cellular signaling networks, leading to the survival of drug-resistant persister clones, and the underlying cause of this resistance is not fully understood.
Combining receptor tyrosine kinase (RTK) inhibitors with SUMOylation inhibitors to treat cancer, where the SUMOylation inhibitors are administered concurrently or separately with RTK inhibitors to target and reverse resistance, thereby enhancing the sensitivity of cancer cells to RTK inhibitors.
The combination of RTK and SUMOylation inhibitors effectively increases the sensitivity of cancer cells to RTK inhibitors, preventing and reversing resistance, thereby improving the responsiveness of malignant tumors to treatment.
Smart Images

Figure US2024031089_05122024_PF_FP_ABST
Abstract
Description
TITLECOMBINED RTK AND SUMO INHIBITION FOR CANCER THERAPYCROSS REFERENCE TO RELATED APPLICATION
[0001] This application claims priority to U.S. Provisional Patent Application Serial No. 63 / 625,815, filed January 26, 2024, entitled “COMBINED RTK AND SUMO INHIBITION FOR CANCER THERAPY,” and U.S. Provisional Patent Application Serial No. 63 / 504,683, filed May 26, 2023, entitled “COMBINED RTK AND ALK INHIBITION IN RTK DRIVEN CANCERS.” The contents of each of the aforementioned applications is hereby incorporated by reference in its entirety.ACKNOWLEDGEMENT OF GOVERNMENT SUPPORT
[0002] This invention was made with government support under Grant Nos. CA244212 and NS119225 awarded by the National Institutes of Health. The government has certain rights in this invention.INCORPORATION OF SEQUENCE LISTING
[0003] The present application contains a Sequence Listing which has been submitted in .XML format via Patent Center and is hereby incorporated by reference in its entirety. Said WIPO Sequence Listing was created on May 19, 2024, is named 106546-800686_Sequence Listing, and is 5 kilobytes in size.BACKGROUND
[0004] 1 . Field
[0005] The present disclosure is directed to compositions and methods of treating delayed RTK inhibitor resistance in certain cancers.
[0006] 2. Background
[0007] Receptor tyrosine kinase (RTK) inhibition is a widely used treatment in cancer and is assumed to render the RTK inactive. However, ultimately many targeted treatments using tyrosine kinase inhibitors (TKIs) (including RTKs) fail because of secondary resistance. Mechanisms of secondary resistance include mutations in RTKs such as the C797S mutation in EGFR in NSCLC or RTK amplification, detected months after initial treatment. RTK inhibition also results in a rapid adaptive reprogramming of cellular signaling networks as the cancer cell tries to restore homeostasis. This rapid adaptive response may lead to the survival of drug resistant persister clones and secondary resistance. For example, it has been shown thatactivation of inflammatory signals such as TNF-NF-KB can mediate resistance to EGFR inhibition in NSCLC. However, the ultimate underlying cause behind RTK drug resistance is unknown. New methods and compositions are needed to treat and reverse RTK inhibitor resistance in patients.SUMMARY
[0008] In an aspect, the current disclosure encompasses a method of treating a cancer in a subject, comprising administering to the subject in need thereof: at least one receptor tyrosine kinase (RTK) inhibitor; and at least one SUMOylation inhibitor, wherein the subject has or is suspected of having a malignant tumor. Examples of RTK inhibitor include epidermal growth factor receptor (EGFR) inhibitor, a HER2 inhibitor, a HER3 inhibitor, a HER4 inhibitor, a pan-HER inhibitor, a platelet-derived growth factor (PDGF) / Kit receptor inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor, a fibroblast growth factor (FGF) receptor inhibitor, a hepatocyte growth factor (HGF receptor) inhibitor, a mesenchymal-epithelial transition factor receptor (MET) inhibitor, an insulin or insulin-like growth factor (IGF) receptor inhibitor or any combination thereof. In an aspect, the at least one RTK inhibitor may comprises a peptide, an antibody, a small molecule, an oligo, a nucleic acid molecule, or any combination thereof. Examples of small molecule RTK inhibitors include osimertinib, imatinib, capmatinib, linsitinib, infigratinib, avapritinib, pemigatinib, ripretinib, selpercatinib, tucatinib, entrectinib, erdafitinib, pexidartinib, dacomitinib, gilteritinib, acalabrutinib, midostaurin, neratinib, cobimetinib, lenvatinib, nintedanib, afatinib, trametinib, axitinib, cabozantinib, ponatinib, regorafenib, tofacitinib, vandetanib, pazopanib, lapatinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, gefitinib, imatinib, varlinitib, infigratinib, mobocertinib, pralsetinib, tepotinib, tivozanib, trastuzumab, aflibercept, larotrectinib, trastuzumab, pertuzumab, amivantamab, bevacizumab, margetuximab, necitumumab, ramucirumab, panitumumab, cetuximab, derivatives thereof, or any combination thereof.
[0009] In another aspect, the method comprises administering at least one SUMOylation inhibitor. Suitable SUMOylation inhibitors include a small peptide, a protein, an antibody, a small molecule, an oligo, a nucleic acid molecule, or any combination thereof. In an aspect, the SUMOylation inhibitors is a small molecule, for example anacardic acid, 2-hydroxy-5- nitrobenzylidene thiazolidine-4-one (2-HNB), ginkgolic acid, N-ethylmaleimide (NEM), SNEP inhibitors, kerriamycin B, compound 21 , davidiin, tannic acid, ML-792, COH-000, TAK-981 , ML-93, GSK145A, 2-D08, spectomycin B, GN6958, SUMO-based Ubc9 inhibitors (SUBINs), triptolide, GN6958, momordin Ic (Me), nocardione A, dunnione, dehydrodunnione, - lapachone, streptonigrin, ebselen, vialinin A and derivatives thereof, or any combination thereof.
[0010] In a further aspect, the RTK inhibitor and the SUMOylation inhibitor may be administered concurrently, or separately.
[0011] In certain aspects, the method may be used for the treatment of a malignant tumor, for example a carcinoma, a sarcoma, a hematological malignancy or any combination thereof. In an aspect, the malignant tumor may comprise a lung tumor, a breast tumor, a pancreatic tumor, a colorectal tumor, an esophageal tumor, a head-and-neck tumor, a hematological malignancy, a brain tumor, an ovarian tumor, a stomach tumor, a gastric tumor, a gastrointestinal stromal tumor, a prostate tumor, a thyroid tumor, bladder tumor, dermatofibrosarcoma protuberans, a giant cell tumor, a lymphoma, melanoma, a myeloma, a kidney tumor, a soft tissue sarcoma, chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), urothelial carcinoma, a cervical tumor, liver or bile duct tumor, endometrial tumor or any combination thereof. In an aspect, the malignant tumor may be derived from a non-small-cell lung cancer (NSCLC), HER-2 positive breast cancer, glioblastoma, gastrointestinal stromal tumor, esophageal tumor, liver or bile duct tumor, bladder tumor, or any combination thereof. In an aspect, the malignant tumor has one or more somatic mutations, translocations, amplifications, and / or other disruptions in at least one gene encoding an RTK, for example EGFR gene, a HER2 gene, a HER3 gene, a HER4 gene, a c- Met gene, a ROS1 gene, a IGF-1 R gene, a TRKA gene, a TRKB gene, a TRKC gene, a PDGFR gene, a VEGFR gene, a FGFR gene, a FLT3 gene, a NTRK gene, a RET gene or any combination thereof.
[0012] The current disclosure further encompasses a pharmaceutical composition comprising at least one receptor tyrosine kinase (RTK) inhibitor and at least one SUMOylation inhibitor and an excipient. The RTK inhibitor may comprise an epidermal growth factor receptor (EGFR) inhibitor, a HER2 inhibitor, a HER3 inhibitor, a HER4 inhibitor, a pan-HER inhibitor, a platelet-derived growth factor (PDGF) / Kit receptor inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor, a fibroblast growth factor (FGF) receptor inhibitor, a hepatocyte growth factor (HGF receptor) inhibitor, a mesenchymal-epithelial transition factor receptor (MET) inhibitor, an insulin or insulin-like growth factor (IGF) receptor inhibitor, or any combination thereof. The pharmaceutical composition disclosed herein may comprise at least one RTK inhibitor comprising a peptide, an antibody, small molecule pharmaceutical compound, an oligo, a nucleic acid molecule, or any combination thereof. Examples of suitable small molecule RTK inhibitor include a small molecule comprising osimertinib, imatinib, capmatinib, linsitinib, infigratinib, avapritinib, pemigatinib, ripretinib, selpercatinib, tucatinib, entrectinib, erdafitinib, pexidartinib, dacomitinib, gilteritinib, acalabrutinib, midostaurin, neratinib, cobimetinib, lenvatinib, nintedanib, afatinib, trametinib, axitinib, cabozantinib, ponatinib, regorafenib, tofacitinib, vandetanib, pazopanib, lapatinib, nilotinib, dasatinib,sunitinib, sorafenib, erlotinib, gefitinib, imatinib, varlinitib, infigratinib, mobocertinib, pralsetinib, tepotinib, tivozanib, trastuzumab, aflibercept, larotrectinib, trastuzumab, pertuzumab, amivantamab, bevacizumab, margetuximab, necitumumab, ramucirumab, panitumumab, cetuximab, derivatives thereof, or any combination thereof. Suitable SUMOylation inhibitors may comprises a small peptide, a protein, an antibody, a small molecule pharmaceutical compound, an oligo, a nucleic acid molecule, or any combination thereof. Examples of small molecule SUMOylation inhibitor include anacardic acid, 2-hydroxy-5-nitrobenzylidene thiazolidine-4-one (2-HNB), ginkgolic acid, N-ethylmaleimide (NEM), SNEP inhibitors, kerriamycin B, compound 21 , davidiin, tannic acid, ML-792, COH-OOO, TAK-981 , ML-93, GSK145A, 2-D08, spectomycin B, GN6958, SUBINs, triptolide, GN6958, momordin Ic (Me), nocardione A, dunnione, dehydrodunnione, p-lapachone, streptonigrin, ebselen, vialinin A and derivatives thereof, or any combination thereof.
[0013] In one aspect, the pharmaceutical composition is for administration into a subject in need thereof, wherein the subject has or is suspected of having a malignant tumor. In an aspect, a malignant tumor may comprise a carcinoma, a sarcoma, a hematological malignancy or any combination thereof. In an aspect, the malignant tumor may comprise a lung tumor, a breast tumor, a pancreatic tumor, a colorectal tumor, an esophageal tumor, a head-and-neck tumor, a hematological malignancy, a brain tumor, an ovarian tumor, a stomach tumor, a gastric tumor, a gastrointestinal stromal tumor, a prostate tumor, a thyroid tumor, bladder tumor, dermatofibrosarcoma protuberans, a giant cell tumor, a lymphoma, melanoma, a myeloma, a kidney tumor, a soft tissue sarcoma, chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), urothelial carcinoma, a cervical tumor, liver or bile duct tumor, endometrial tumor or any combination thereof.
[0014] In another aspect, the pharmaceutical composition may be formulated for parenteral, oral or transmucosal delivery.
[0015] In further aspect, the disclosure encompasses a method of treating a tumor in a subject in need thereof comprising administering to the subject at least one SUMOylation inhibitor, wherein the subject has undergone, is undergoing or will undergo an anti-cancer therapy comprising one or more targeted receptor tyrosine kinase (RTK) inhibitors. In an aspect, the tumor is resistant to or may develop resistance to the anti-cancer therapy comprising one or more targeted RTK inhibitors. In an aspect, the targeted RTK inhibitor is an EGFR / ERBB inhibitor. In an aspect the subject responds to the RTK inhibitor over a longer time period than a subject that did not receive the SUMOylation inhibitor.
[0016] The disclosure further encompasses a method of preventing sensitization and / or resistance to an anti-cancer therapy comprising a receptor tyrosine kinase (RTK) inhibitor, themethod comprising administering to a subject in need thereof, an SUMOylation inhibitor prior to or concurrent with the anti-cancer therapy comprising the RTK inhibitor.
[0017] Additionally, provided herein is a method of increasing sensitivity of a cancer cell to a receptor tyrosine kinase (RTK) inhibitor comprising: contacting a cancer cell with at least one SUMOylation inhibitor, where the cancer cell is sensitized and / or resistant to a receptor tyrosine kinase (RTK) inhibitor, with at least one SUMOylation inhibitor increases the cell’s sensitivity to an RTK inhibitor as compared to a cell not contacted with the SUMOylation inhibitor. In one aspect of the method, the cell survival of the cancer cell is decreased after contacting the cancer cell with at least one SUMOylation inhibitor. In one aspect, the cell proliferation of the cancer cell is decreased after contacting the cancer cell with at least one SUMOylation inhibitor.
[0018] Other technical features may be readily apparent to one skilled in the art from the following figures, descriptions, and claims.BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Aspects of the present disclosure are illustrated by way of example and in which:
[0020] FIG. 1A is a representative heatmap indicating proteins that bind to EGFR in cells after osimertinib treatment.
[0021] FIG. 1B-1D are representative immunoblots showing association of SUMO3 and EGFR in HCC827 cells (FIG. 1 B), PC9 cells (FIG. 1C), and H3255 cells (FIG. 1 D) after treatment with Osimertinib and immunoprecipitation with EGFR antibody.
[0022] FIG. 1E-1F are representative immunoblots showing association of SUMO3 and EGFR in HCC827 xenograft tumor tissue (FIG. 1 E) and HCC4190 PDX xenograft tumor tissue (FIG. 1 F) after treatment with Osimertinib and immunoprecipitation with EGFR antibody.
[0023] FIG. 1G-1I are representative immunoblots showing lack of association of SUMO3 and EGFR in HCC827 cells (FIG. 1G), PC9 cells (FIG. 1 H) and H3255 cells (FIG. 11) that were transfected with SUMO3 siRNA, treated with osimertinib, and immunoprecipitated with EGFR antibody.
[0024] FIG. 1J-1 K are representative immunoblots showing lack of association of SUMO3 and EGFR in HCC827 cells (FIG. 1 J) and PC9 cells (FIG. 1 K) that were transfected with Flag- SENP2 and then treated with 100 nM and 50 nM Osimertinib, respectively, followed by immunoprecipitation with EGFR antibody.
[0025] FIG. 1L-1 M are representative immunoblots showing lack of association of SUMO1(FIG. 1 L) or SUMO 2 (FIG. 1 M) with HCC827 cells upon Osimertinib treatment. Cells were treated with 100nM Osimertinib, followed by immunoprecipitation with EGFR anytibody and western blot.
[0026] FIG. 1N-1O are representative immunoblots showing lack of association of SUMO1 (FIG. 1 N) or SUMO 2 (FIG. 10) with PC9 cells upon Osimertinib treatment. Cells were treated with 100nM Osimertinib, followed by immunoprecipitation with EGFR antibody and western blot.
[0027] FIG. 1P are representative immunoblots showing that osimertinib does not affect EGFR stability. HCC827, PC9 and H3255 cells were treated with 100 nM or 50 nM osimertinib, respectively, followed by Western blot. HCC827 cells were treated with actinomycin D and osimertinib, followed by collection of lysates and Western blot. A similar experiment was performed in PC9 cells. Osi, Osimertinib, ActD, actinomycin.
[0028] FIG. 1Q-1S are representative immunoblots showing that EGFR SUMOylation can be detected in response to erlotinib. HCC827 (FIG. 1Q), PC9 (FIG. 1 R) and H3255 (FIG. 1S) cells were treated with 100 nM erlotinib, followed by immunoprecipitation with EGFR antibody and Western blot.
[0029] FIG. 1T-1U are representative immunoblots showing association of SUMO3 with BT474 cells (FIG. 1T) and SK-BR-3 (FIG. 1 U) following 1 pM lapatinib treatment and immunoprecipitation with ERBB2 antibody.
[0030] FIG. 1V-1W are representative immunoblots showing association of SUMO3 with H1993 cells (FIG. 1V) and EBC-1 (FIG. 1W). H1993 and EBC-1 cells were treated with 1 pM or 100 nM capmatinib, respectively, followed by immunoprecipitation with MET antibody and Western blot.
[0031] FIG. 1X-1Y are representative immunoblots showing association of SUMO3 with RT112 cells (FIG. 1X) and RT4 (FIG. 1Y). H1993 and EBC-1 cells were treated with 1 pM infigratinib, followed by immunoprecipitation with FGFR3 antibody and Western blot.
[0032] FIG. 1Z are representative immunoblots showing immunoprecipitation of H2228 cells treated with 1 uM alectinib, with ALK antibody and Western blot.
[0033] FIG. 1AA are representative immunoblots showing immunoprecipitation of H1703 cells treated with 1 pM Imatinib, with PDGFRa antibody and Western blot.
[0034] FIG. 2A-2C are representative bar graphs indicating fold-change in TNF mRNA transcript levels as measured by qPCR in HCC827 cells (FIG. 2A), PC9 cells (FIG. 2B), and H3255 cells (FIG. 2C) that were transfected with control or SUMO3 siRNA for 48 hours followed by osimertinib treatment for 48 hours. Insets show illustrative immunoblot of SUMO3expression in siRNA treated cells. Three independent experiments show each result and mean ± SEM. ***p < 0.001 , ****p < 0.0001 , by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test.
[0035] FIG. 2D-2F are representative plots indicating fold-change in TNF protein levels in supernatant as measured by ELISA in HCC827 cells (FIG. 2D), PC9 cells (FIG. 2E), and H3255 cells (FIG. 2F) that were transfected with control or SLIMO3 siRNA for 48 hours followed by osimertinib treatment for 48 hours. Insets show illustrative immunoblot of SLIMO3 expression in siRNA treated cells. Three independent experiments show each result and mean ± SEM. ***p < 0.001 , ****p < 0.0001 , by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test.
[0036] FIG. 2G-2I are representative plots indicating relative NF-KB activity as measured by dual-luciferase assay in HCC827 cells (FIG. 2G), PC9 cells (FIG. 2H), and H3255 cells (FIG. 2I) that were transfected with control or SLIMO3 siRNA for 48 hours followed by osimertinib treatment for 48 hours. Insets show illustrative immunoblot of SLIMO3 expression in siRNA treated cells. Three independent experiments show each result and mean ± SEM. ***p < 0.001 , ****p < 0.0001 , by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test.
[0037] FIG. 2J-2K are representative bar graphs indicating fold-change in TNF mRNA transcript levels as measured by qPCR in HCC827 cells (FIG. 2J) and PC9 cells (FIG. 2K) that were transfected with control or EGFR siRNA for 48 hours followed by osimertinib treatment for 48 hours. Insets show illustrative immunoblot of EGFR expression in siRNA treated cells. Statistical significance was determined using two-tailed unpaired Student’s t-test, **p < 0.01 ; ***p < 0.001 ; ****p < 0.0001 ; and n.s, not significant. Osi, osimertinib.
[0038] FIG. 2L-2M are representative plots indicating fold-change in TNF protein levels in supernatant as measured by ELISA in HCC827 cells (FIG. 2L) and PC9 cells (FIG. 2M), that were transfected with control or EGFR siRNA for 48 hours followed by osimertinib treatment for 48 hours. Insets show illustrative immunoblot of EGFR expression in siRNA treated cells. Statistical significance was determined using two-tailed unpaired Student’s t-test, **p < 0.01 ; ***p < 0.001 ; ****p < 0.0001 ; and n.s, not significant. Osi, osimertinib.
[0039] FIG. 2N-2O are representative plots indicating relative NF-KB activity as measured by dual-luciferase assay in HCC827 cells (FIG. 2N) and PC9 cells (FIG. 20) that were transfected with control or EGFR siRNA for 48 hours followed by osimertinib treatment for 48 hours. Insets show illustrative immunoblot of EGFR expression in siRNA treated cells. Statistical significance was determined using two-tailed unpaired Student’s t-test, **p < 0.01 ; ***p < 0.001 ; ****p < 0.0001 ; and n.s, not significant. Osi, osimertinib.
[0040] FIG. 3A-3B are representative immunoblots of HCC827 cells (FIG. 3A) and PC9 cells(FIG. 3B) following osimertinib treatment and immunoprecipitation with TRIM28 antibody.
[0041] FIG. 3C-3D are representative immunoblots of HCC827 cells (FIG. 30) and PC9 cells (FIG. 3D) that were transfected with control or TRIM28 siRNA followed by 100 nM osimertinib treatment and immunoprecipitation with EGFR antibody.
[0042] FIG. 3E-3F are representative immunoblots of HCC827 cells (FIG. 3E) and PC9 cells (FIG. 3F) that were transfected with control or LIBC9 siRNA followed by 100 nM osimertinib treatment and immunoprecipitation with EGFR antibody.
[0043] FIG. 4A-4B are representative immunoblots showing EGFR expression in H661 cells (FIG. 4A) and H1975_EGFRKO cells (FIG. 4B) stably transfected with vectors encoding Del, Del_K37R, L858R, L858_K37R mutant EGFRs.
[0044] FIG. 4C-4D are representative immunoblots showing EGFR activity (pEGFR levels) in Del and Del_K37R expressing H661 cells (FIG. 4G) and Del and Del_K37R expressing EGFRKO H1975 cells (FIG. 4D) following treatment with EGF for 5 min.
[0045] FIG. 4E-4F are representative immunoblots showing that mutation of the K37 residue inhibits osimertinib-induced EGFR SUMOylation. L858R (FIG. 4E) and L858R_K37R (FIG. 4F) expressing H661 and EGFRKO H1975 cells were treated with EGF (50 ng / ml) for 5 min, followed by Western blot.
[0046] FIG. 4G-4H are representative immunoblots of Del and Del_K37R expressing H661 cells (FIG. 4G) and Del and Del_K37R expressing EGFRKO H1975 cells (FIG. 4H) following Osimertinib treatment and immunoprecipitation with EGFR antibody.
[0047] FIG. 4I-4J are representative immunoblots showing that mutation of the K37 residue inhibits osimertinib-induced EGFR SUMOylation. L858R (FIG. 4A) and L858R_K37R (FIG. 4B) expressing H661 and EGFRKO H1975 cells were treated with 100 nM osimertinib, followed by immunoprecipitation with EGFR antibody and Western blot.
[0048] FIG 4K is a representative bar graph indicating fold-change in TNF mRNA transcript levels as measured by qPCR in Del and Del_K37R expressing H661 cells following Osimertinib treatment.
[0049] FIG. 4L is a representative plot indicating relative NF-KB activity as measured by dual-luciferase assay in Del and Del_K37R expressing H661 cells following Osimertinib treatment.
[0050] FIG. 4M is a representative bar graph indicating fold-change in TNF mRNA transcript levels as measured by qPCR in Del and Del_K37R expressing EGFRKO H1975 cells following Osimertinib treatment.
[0051] FIG. 4N is a representative plot indicating relative NF-KB activity as measured by dual-luciferase assay in Del and Del_K37R expressing EGFRKO H1975 cells following Osimertinib treatment.
[0052] FIG 40 is a representative bar graph indicating fold-change in TNF mRNA transcript levels as measured by qPCR in L858R and L858R_K37R expressing H661 cells following Osimertinib treatment. Three independent experiments show each result and mean ± SEM. **p < 0.01 ; ***p < 0.001 and n.s, not significant, by two-tailed unpaired Student’s t-test (E-H).
[0053] FIG. 4P is a representative plot indicating relative NF-KB activity as measured by dual-luciferase assay in L858R and L858R_K37R expressing H661 cells following Osimertinib treatment. Three independent experiments show each result and mean ± SEM. **p < 0.01 ; ***p < 0.001 and n.s, not significant, by two-tailed unpaired Student’s t-test (E-H).
[0054] FIG. 4Q is a representative bar graph indicating fold-change in TNF mRNA transcript levels as measured by qPCR in L858R and L858R_K37R expressing EGFRKO H1975 cells following Osimertinib treatment. Three independent experiments show each result and mean ± SEM. **p < 0.01 ; ***p < 0.001 and n.s, not significant, by two-tailed unpaired Student’s t-test (E-H).
[0055] FIG. 4R is a representative plot indicating relative NF-KB activity as measured by dual-luciferase assay in L858R and L858R_K37R expressing EGFRKO H1975 cells following Osimertinib treatment. Three independent experiments show each result and mean ± SEM. **p < 0.01 ; ***p < 0.001 and n.s, not significant, by two-tailed unpaired Student’s t-test (E-H).
[0056] FIG. 4S-4T are representative immunoblots of HCC827 cells (FIG. 4K) and PC9 cells (FIG. 4L) that were transfected with HA-Del and HA-Del-K37R, followed by osimertinib treatment and immunoprecipitation with HA antibody.
[0057] FIG. 4U-4V are representative immunoblots showing that EGFR is present in cytosolic fraction in EGFR mutant NSCLC cells. HCC827 (FIG. 4U) and PC9 (FIG. 4V) cells were treated with 100 nM osimertinib, followed by cell fractionation and Western blot.
[0058] FIG. 4W-4X are representative immunoblots showing that EGFR is present in cytosolic fraction in EGFR mutant NSCLC cells. HCC827 (FIG. 4W) and PC9 (FIG. 4X) cells were treated with 100 nM osimertinib, followed by cell fractionation and Western blot of the cytosolic fraction with EGFR antibody.
[0059] FIG. 5A-5B are representative immunoblots showing that EGFR inhibition leads to a SUMOylation dependent activation of NF-KB by recruiting a RIPK1 signaling complex. HCC827 (FIG. 5A) and PC9 (FIG. 5B) cells were treated with 100 nM osimertinib, followed by immunoprecipitation with RIPK1 antibody and Western blot.
[0060] FIG. 5C-5D are representative immunoblots showing that EGFR inhibition leads to a SUMOylation dependent activation of NF-KB by recruiting a RIPK1 signaling complex. HCC827 (FIG. 50) and PC9 (FIG. 5D) cells were transfected with siRNA control or siRNA SLIMO3, then treated with 100 nM osimertinib, followed by immunoprecipitation with RIPK1 antibody and Western blot.
[0061] FIG. 5E-5F are representative immunoblots showing that EGFR inhibition leads to a SUMOylation dependent activation of NF-KB by recruiting a RIPK1 signaling complex. Del and Del_K37R expressing EGFRKO H1975 (FIG. 5E) and H661 (FIG. 5F) cells were treated with 100 nM osimertinib, followed by immunoprecipitation with RIPK1 antibody and Western blot.
[0062] FIG. 5G-5H are representative plot indicating relative NF-KB activity as measured by dual-luciferase assay in HCC827 and PC9 cells. HCC827 and PC9 cells were transfected with RIPK1 or control siRNA for 48 hr, followed by 100 nM of osimertinib treatment for 24 hr and then NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. Three independent experiments show each result and mean ± SEM. ***p < 0.001 , by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test.
[0063] FIG. 6A-6L provides data showing that RTK inhibition of multiple RTKs results in a SUMOylation dependent NF-KB activation and TNF upregulation. FIG. 6A is a bar graph showing TNF mRNA fold change in BT474 cells. BT474 cells were transfected with SUMO3 or control siRNA for 48 hr, then treated with 1 pM lapatinib for 24 hr and followed by qPCR to detect TNF mRNA. FIG. 6B is a dot graph showing relative NF- KB activity in BT474 cells. BT474 cells were transfected with SUMO3 or control siRNA for 48 hr, then treated with 1 pM lapatinib for 24 hr and NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. FIG. 6C is a bar graph showing TNF mRNA fold change in SK-BR-3 cells. SK-BR-3 cells were transfected with SUMO3 or control siRNA for 48 hr, then treated with 1 pM lapatinib for 24 hr and followed by qPCR to detect TNF mRNA. FIG. 6D is a dot graph showing relative NF- KB activity in SK-BR-3 cells. SK-BR-3 cells were transfected with SUMO3 or control siRNA for 48 hr, then treated with 1 pM lapatinib for 24 hr and NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. FIG. 6E is a bar graph showing TNF mRNA fold change in H1993 cells. H1993 cells were transfected with SUMO3 or control siRNA for 48 hr, then treated with 1 pM capmatinib for 48 hr and followed by qPCR to detect TNF mRNA. FIG. 6F is a dot graph showing relative NF- KB activity in H1993 cells. H1993 cells were transfected with SUMO3 or control siRNA for 48 hr, then treated with 1 pM capmatinib for 24 hr and NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. FIG. 6G: is a bar graph showing TNF mRNA fold change in H2228 cells. H2228 cells were transfected with SUMO3 or control siRNA for 48 hr, then treated with 1 pM alectinib for 24 hrand followed by qPCR to detect TNF mRNA. FIG. 6H is a dot graph showing relative NF- KB activity in H2228 cells H2228 cells were transfected with SLIMO3 or control siRNA for 48 hr, then treated with 1 M alectinib for 24 hr and NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. FIG. 6I a bar graph showing TNF mRNA fold change in RT 112 cells. RT 112 cells were transfected with SLIMO3 or control siRNA for 48 hr, then treated with 1 pM infigratinib for 24 hr and followed by qPCR to detect TNF mRNA. FIG. 6J is a dot graph showing relative NF- KB activity in RT112 cells. RT112 cells were transfected with SLIMO3 or control siRNA for 48 hr, then treated with 1 pM infigratinib for 24 hr and NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. FIG. 6K is a bar graph showing TNF mRNA fold change in H1703 cells. H1703 cells treated with 1 pM imatinib, and then qPCR was performed to detect TNF mRNA. FIG. 6L is a dot graph showing relative NF- KB activity in H1703 cells H1703 cells treated with 1 pM imatinib, and then NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. Three independent experiments show each result and mean ± SEM. **p < 0.01 , ***p < 0.001 , ****p < 0.0001 , by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test (A-J). Statistical significance was determined using one-way analysis of variance (ANOVA), adjusted by Bonferroni’s test (K-L), n.s, not significant.
[0064] FIG. 6M-6R are enrichment plots providing gene set enrichment analysis (GSEA) showing TNF signaling is enriched in multiple RTK mutant or rearranged cell lines treated with corresponding TKI. Gene set enrichment analysis (GSEA). Osimertinib treated PC9 (FIG. 6M) and HCC827 (FIG. 6N) RNAseq data ware obtained from GSE193258. TNF signaling network was derived from the Reactome Pathway Database. Lapatinib treated SK-BR-3 (FIG. 60) and BT474 (FIG. 6P) RNAseq data were obtained from GSE160001 and GSE84896. Similar anaylsis were conducted on capmati nib- treated MET amplified EBC-1 (FIG. 6Q) cell line (GSE94405) and crizotinib-treated ALK-rearranged H3122 cell line (GSE64741).
[0065] FIG. 7A-7N are photographs of representative immunoblots showing that bypass RTK signaling is SUMOylation dependent. FIG. 7A: PC9 cells were transfected with siRNA control or siRNA SLIMO3, then treated with 100 nM osimertinib, cell lysates were collected and Western blot was performed. FIG. 7B: Del and Del_K37R expressing EGFRKO H1975 cells were treated with 100 nM osimertinib, cell lysates were collected, and Western blot was performed. H1993 (FIG. 7C), BT474 (FIG. 7D), SK-BR-3 (FIG. 7E), RT112 (FIG. 7F) and H2228 (FIG. 7G) cells were transfected with siRNA control or siRNA SLIMO3, then treated with 1 pM capmatinib, 300 nM lapatinib, 1 pM infigratinib or 100 nM alectinib, respectively, cell lysates were collected and Western blot was performed. PC9 (FIG. 7H), BT474 (FIG. 7I), and H1993 (FIG. 7J) cells were transfected with siRNA EGFR, siRNA ERBB2 or siRNA MET,respectively, cell lysates were collected at indicated times and Western blot was performed. PC9 (FIG. 7K) cells were transfected with siRNA control or siRNA SLIMO3, then treated with 100 nM osimertinib, followed by immunoprecipitation with EGFR antibody and Western blot. FIG. 7L: Del and Del_K37R expressing EGFRKO H1975 cells were treated with 100 nM osimertinib, followed by immunoprecipitation with EGFR antibody and Western blot. FIG. 7M: BT474 cells were transfected with siRNA control or siRNA SLIMO3, then treated with 300 nM lapatinib, followed by immunoprecipitation with ERBB2 antibody and Western blot. FIG. 7N: H1993 cells were transfected with siRNA control or siRNA SLIMO3, then treated with 1 pM capmatinib, followed by immunoprecipitation with MET antibody and Western blot.
[0066] FIG. 8A-8B are photographs of representative immunoblots showing She and Grb2 association with bypass RTKs in PC9 cells. PC9 cells were transfected with siRNA control or siRNA SLIMO3, then treated with 100 nM osimertinib, followed by immunoprecipitation with SHC (FIG. 8A) or GRB2 (FIG. 8B) antibody, respectively, and Western blot was performed.
[0067] FIG. 8C-8D are photographs of representative immunoblots showing She and Grb2 association with bypass RTKs in H1975 EGFRKO cells. Del and Del_K37R expressing EGFRKO H1975 cells were treated with 100 nM osimertinib, followed by immunoprecipitation with SHC (FIG. 8C) or GRB2 (FIG. 8D) antibody, respectively, and Western blot was performed.
[0068] FIG. 8E-8F are photographs of representative immunoblots showing She and Grb2 association with bypass RTKs in BT474 cells. BT474 cells were transfected with siRNA control or siRNA SLIMO3, then treated with 300 nM lapatinib, followed by immunoprecipitation with SHC or GRB2 antibody, respectively, and Western blot was performed.
[0069] FIG. 8G-8H are photographs of representative immunoblots showing She and Grb2 association with bypass RTKs in H1993 cells. H1993 cells were transfected with siRNA control or siRNA SLIMO3, then treated with 1 pM capmatinib, followed by immunoprecipitation with SHC or GRB2 antibody, respectively, and Western blot was performed.
[0070] FIG. 9A-9B are photographs of representative immunoblots showing EGFR SUMOylation in secondary resistant cell lines. HCC827 parental, HCC827 erlotinib-resistant, H1975 parental and H1975 osimertinib-resistant cells were collected and immunoprecipitated with EGFR antibody, followed by Western blot.
[0071] FIG. 9C is a bar graph of qPCR data showing EGFR SUMOylation in secondary resistant cell lines. H1975 parental and H1975 osimertinib-resistant cells were collected and followed by qPCR to detect TNF mRNA. Three independent experiments show each result and mean ± SEM. **p < 0.01 ; ***p < 0.001 , by two-tailed unpaired Student’s t-test.
[0072] FIG. 9D is a dot graph showing dual luciferase reporter assay data showing EGFR SUMOylation in secondary resistant cell lines. H1975 parental and H1975 osimertinib- resistant cells were collected and then NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. Three independent experiments show each result and mean ± SEM. **p < 0.01 ; ***p < 0.001 , by two-tailed unpaired Student’s t-test.
[0073] FIG. 9E-9F is a series of line graphs that are representative plots showing H1975 osimertinib-resistant cells were transfected with siRNA control (FIG. 9E) and siRNA SLIMO3 (FIG. 9F), then treated with osimertinib, followed by AlamarBlue cell viability assay. Three independent experiments show each result and mean ± SEM. ****p < 0.0001 by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test.
[0074] FIG. 10A-10B is a series of line graphs that are representative plots showing percentage viability of osimertinib treated H1975 (FIG. 10A) and PC9 (FIG. 10B) cells. HCC827 and PC9 cells were transfected with SLIMO3 or control siRNA for 48 hr, then treated with indicated concentrations of osimertinib, followed by AlamarBlue cell viability assay. Three independent experiments show each result and mean ± SEM. ****p < 0.0001 by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test.
[0075] FIG. 10C-10F is a series of line graphs that are representative plots showing percentage viability of osimertinib treated H661 and EGFRKO H1975 (FIG. 10B) cells. AlamarBlue cell viability assays were conducted with stably expressed Del, Del_K37R in H661 cells (FIG. 10C); Del, Del_K37R in EGFRKO H 1975 cells (FIG. 10D); L858R and L858R_K37R in H661 (FIG. 10E); and L858R and L858R_K37R in EGFRKO H1975 (FIG. 10F) cells. Three independent experiments show each result and mean ± SEM. ****p < 0.0001 by two-way analysis of variance (ANOVA), adjusted by Bonferroni’s test.
[0076] FIG. 10G is a line graph and a photograph showing the tumor volume in osimertinib treated mice injected with EGFR_del or EGFR_del K37R H1975_EGFR KO cells. Athymic mice were injected s.c. with 2 x 106EGFR_del or EGFR_del K37R H1975_EGFR KO cells. When tumors formed, mice were randomly divided into 4 groups (EGFR_del control, EGFR_del osimertinib, EGFR_del K37R control, EGFR_del K37R osimertinib, n=6 per group). The mice were treated with 0.25 mg / kg osimertinib by oral gavage for 30 consecutive days. Tumor sizes are shown as mean volume ± SEM. ****p < 0.0001 by repeated measures (RM) two-way ANOVA, adjusted by Bonferroni’s test.
[0077] FIG. 10H is a line graph and a photograph showing the tumor volume in osimertinib treated mice injected with 106EGFR_del or EGFR_del K37R H661 cells. Athymic mice were injected s.c. with 5 x 106EGFR_del or EGFR_del K37R H661 cells. When tumors formed, micewere randomly divided into 4 groups (EGFR_del control, EGFR_del osimertinib, EGFR_del K37R control, EGFR_del K37R osimertinib, n=6 per group). The mice were treated with 1 mg / kg osimertinib by oral gavage for 30 consecutive days. Tumor sizes are shown as mean volume ± SEM. ****p < 0.0001 by repeated measures (RM) two-way ANOVA, adjusted by Bonferroni’s test.
[0078] FIG. 101 is a line graph and a photograph showing the tumor volume in osimertinib or TAK-981 treated mice injected with PC9 cells. Athymic mice were injected s.c. with 5 x 106PC9 cells, when tumors formed, mice were randomly divided into 4 groups (n=6 per group). The mice were treated with 0.25 mg / kg osimertinib (oral gavage, every day) and / or 7.5 mg / kg TAK-981 (intraperitoneally twice per week). Tumor sizes are shown as mean volume ± SEM. ****p < 0.0001 by repeated measures (RM) two-way ANOVA, adjusted by Bonferroni’s test.
[0079] FIG. 10J is a line graph and a photograph showing the tumor volume in Osimertinib or TAK-981 treated mice implanted with HCC4190 EGFR_L858R NSCLC PDX. , HCC4190 EGFR_L858R NSCLC PDX was implanted s.c. into NOD / SCID mice. When tumors formed, mice were divided into 4 groups (n=6 per group) and treated with 5 mg / kg osimertinib (oral gavage, every day) and / or 7.5 mg / kg TAK-981 (intraperitoneally twice per week). Tumor sizes are shown as mean volume ± SEM. ****p < 0.0001 by repeated measures (RM) two-way ANOVA, adjusted by Bonferroni’s test.
[0080] FIG. 11A-11 B are representative images of PLA analysis of EGFR and SLIMO3 in HCC827 cells (FIG. 11 A) or paraffin-embedded HCC827 tumor slides (FIG. 11 B).
[0081] FIG. 11C-11 D are representative images of PLA analysis of EGFR and SUMO3 in paraffin-embedded human tumor slides from three patients that are EGFR-TKI naive (FIG. 11C) or treated with EGFR- TKI (FIG. 11 D).
[0082] FIG. 11 E-11 F aret representative images of PLA analysis of pre- and post-TKI treated tissue from the same patient (two patients examined, as provided in FIG. 11 E and FIG. 11 F respectively).
[0083] FIG. 11G is a dot graph showing quantitation of PLA positive staining in TKI naive (n=9) and TKI treated (n=20) tissue from 27 patients. Data are represented as mean ± SEM from three independent experiments. Statistical significance was determined by Mann- Whitney U test (G), ****p< 0.0001.DETAILED DESCRIPTION
[0001] The following detailed description references the accompanying drawings that illustrate various aspects of the present disclosure. The drawings and description are intended to describe aspects and aspects of the present disclosure in sufficient detail to enable thoseskilled in the art to practice the present disclosure. Other components can be utilized, and changes can be made without departing from the scope of the present disclosure. The following description is, therefore, not to be taken in a limiting sense.
[0002] The instant disclosure is based, in part, on the surprising discovery that RTKs do not become inert after tyrosine kinase inhibitor (TKI) treatment. Instead, RTKs undergo rapid addition of small ubiquitin-related modifier (SUMO) peptide or SUMOylation in response to tyrosine kinase inhibition and continue to signal by converting to adaptor platforms that recruit multiple proteins and drive therapeutic resistance. Notably, RTK SUMOylation is detected upon kinase inhibition of multiple RTKs and may represent a general consequence of TKI treatment that drives adaptive resistance. Surprisingly, it has been shown that SUMOylation inhibitors can reverse this effect and restore sensitivity to RTKs.
[0003] Accordingly, provided herein are compositions and methods for treating cancer and, in some aspects, a malignant tumor. In some aspects, the compositions herein comprise an RTK inhibitor. In some aspects, the compositions herein comprise an SUMOylation inhibitor. In various aspects, the methods herein comprise administering the SUMOylation inhibitor to a subject in need thereof concurrently with or after a treatment with the RTK inhibitor. In various aspects, the methods herein ultimately prevent treatment resistance and improve responsiveness of a cancer to the RTK inhibitor treatment.
[0084] I. Terminology
[0004] The phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting. For example, the use of a singular term, such as, “a” is not intended as limiting of the number of items. Also, the use of relational terms such as, but not limited to, “top,” “bottom,” “left,” “right,” “upper,” “lower,” “down,” “up,” and “side,” are used in the description for clarity in specific reference to the figures and are not intended to limit the scope of the present disclosure or the appended claims.
[0085] Any term of degree such as, but not limited to, “substantially” as used in the description and the appended claims, should be understood to include an exact, or a similar, but not exact configuration. For example, “a substantially planar surface” means having an exact planar surface or a similar, but not exact planar surface. Similarly, the terms “about” or “approximately,” as used in the description and the appended claims, should be understood to include the recited values or a value that is three times greater or one third of the recited values. For example, about 3 mm includes all values from 1 mm to 9 mm, and approximately 50 degrees includes all values from 16.6 degrees to 150 degrees. For example, they can refer to less than or equal to ± 5%, such as less than or equal to ± 2%, such as less than or equal to ± 1 %, such as less than or equal to ± 0.5%, such as less than or equal to ± 0.2%, such asless than or equal to ± 0.1 %, such as less than or equal to ± 0.05%.
[0086] The terms “comprising,” “including” and “having” are used interchangeably in this disclosure. The terms “comprising,” “including” and “having” mean to include, but not necessarily be limited to the things so described.
[0087] The terms “or” and “and / or,” as used herein, are to be interpreted as inclusive or meaning any one or any combination. Therefore, “A, B or C” or “A, B and / or C” mean any of the following: “A,” “B” or “C”; “A and B”; “A and C”; “B and C”; “A, B and C.” An exception to this definition will occur only when a combination of elements, functions, steps or acts are in some way inherently mutually exclusive.
[0088] Unless defined otherwise, all technical and scientific terms used herein have the meaning commonly understood by a person skilled in the art to which this disclosure belongs. The following references provide one of skill with a general definition of many of the terms used in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991), all of which are incorporated by reference herein. As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.
[0089] The phraseology and terminology employed herein are for the purpose of description and should not be regarded as limiting. When introducing elements of the present disclosure or the preferred aspects(s) thereof, the articles “a”, “an”, “the” and “said” are intended to mean that there are one or more of the elements. The terms “comprising”, “including” and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements. Wherever the terms “comprising” or “including” are used, it should be understood the disclosure also expressly contemplates and encompasses additional aspects “consisting of” the disclosed elements, in which additional elements other than the listed elements are not included.
[0090] The term “about” or “approximately,” as used herein, can mean within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation, per the practice in the given value. Where particular values are described in the application and claims, unless otherwise stated the term “about” can mean an acceptable error range for the particular value, such as 10% of the value modified by the term “about.” As used herein, the term “about,” can mean relative to the recited value, e.g., amount, dose,temperature, time, percentage, etc., ±10%, ±9%, ±8%, ±7%, ±6%, ±5%, ±4%, ±3%, ±2%, or ±1 %.
[0005] Further, as the present disclosure is susceptible to aspects of many different forms, it is intended that the present disclosure be considered as an example of the principles of the present disclosure and not intended to limit the present disclosure to the specific aspects shown and described. Any one of the features of the present disclosure may be used separately or in combination with any other feature. References to the terms “aspect,” “aspects,” and / or the like in the description mean that the feature and / or features being referred to are included in, at least, one aspect of the description. Separate references to the terms “aspect,” “aspects,” and / or the like in the description do not necessarily refer to the same aspect and are also not mutually exclusive unless so stated and / or except as will be readily apparent to those skilled in the art from the description. For example, a feature, structure, process, step, action, or the like described in one aspect may also be included in other aspects but is not necessarily included. Thus, the present disclosure may include a variety of combinations and / or integrations of the aspects described herein. Additionally, all aspects of the present disclosure, as described herein, are not essential for its practice. Likewise, other systems, methods, features, and advantages of the present disclosure will be, or become, apparent to one with skill in the art upon examination of the figures and the description. It is intended that all such additional systems, methods, features, and advantages be included within this description, be within the scope of the present disclosure, and be encompassed by the claims.
[0006] Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise-indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. For example, if a concentration range is stated as 1 % to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification. These are only examples of what is specifically intended, and all possible combinations of numerical values between and including the lowest value and the highest value enumerated are to be considered to be expressly stated in this disclosure.
[0091] As used herein, "treatment," "therapy" and / or "therapy regimen" refer to the clinical intervention made in response to a disease, disorder or physiological condition manifested by a patient or to which a patient may be susceptible. The aim of treatment includes the alleviation or prevention of symptoms, slowing or stopping the progression or worsening of a disease, disorder, or condition and / or the remission of the disease, disorder or condition.
[0092] As used herein, “prevent” or “prevention” refers to eliminating or delaying the onsetof a particular disease, disorder or physiological condition, or to the reduction of the degree of severity of a particular disease, disorder or physiological condition, relative to the time and / or degree of onset or severity in the absence of intervention.
[0093] The term “effective amount" or "therapeutically effective amount" refers to an amount sufficient to effect beneficial or desirable biological and / or clinical results.
[0094] As used herein, “individual”, “subject”, “host”, and “patient” can be used interchangeably herein and refer to any mammalian subject for whom diagnosis, treatment, prophylaxis or therapy is desired, for example, humans, pets, livestock, horses or other animals. As used herein, the term "subject" and "patient" are used interchangeably herein and refer to both human and nonhuman animals. The term "nonhuman animals" of the disclosure includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dog, cat, horse, cow, chickens, amphibians, reptiles, and the like. In some aspects, the subject can be a human. In other aspects, the subject can be a human in need of treating a cancer (e.g., a melanoma).
[0095] The term “administration” and variants thereof (e.g., “administering” a composition) in reference to a composition of the disclosure means introducing the composition or a prodrug of the composition into the system of the subject in need of treatment. When a composition of the disclosure or prodrug thereof is provided in combination with one or more other active agents (e.g., a cytotoxic agent, etc.), “administration” and its variants are each understood to include concurrent and sequential introduction of the composition or prodrug thereof and other agents. The present disclosure includes within its scope prodrugs of the compositions of this disclosure. In general, such prodrugs will be functional derivatives of the compositions of this disclosure which are readily convertible in vivo into the required composition. Thus, in the methods of treatment of the present disclosure, the term “administering” shall encompass the treatment of the various conditions described with the composition specifically disclosed or with a composition which may not be specifically disclosed, but which converts to the specified composition in vivo after administration to the patient.
[0096] The term “therapeutically effective amount” as used herein means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue, system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
[0097] As used herein, the term “treating” refers to the application or administration of a composition including one or more active agents to a subject, who is in need of the treatment, for example, having a target disease or disorder, a symptom of the disease / disorder, or a predisposition toward the disease / disorder, with the purpose to cure, heal, alleviate, relieve,alter, remedy, ameliorate, improve, or affect the disorder, the symptom of the disease, or the predisposition toward the disease or disorder. Alleviating a target disease / disorder includes delaying the development or progression of the disease or reducing disease severity. Alleviating the disease does not necessarily require curative results. As used therein, “delaying” the development of a target disease or disorder means to defer, hinder, slow, retard, stabilize, and / or postpone progression of the disease. This delay can be of varying lengths of time, depending on the history of the disease and / or individuals being treated. A method that “delays” or alleviates the development of a disease, or delays the onset of the disease, is a method that reduces probability of developing one or more symptoms of the disease in a given time frame and / or reduces extent of the symptoms in a given time frame, when compared to not using the method. Such comparisons are typically based on clinical studies, using a number of subjects sufficient to give a statistically significant result.
[0098] As used interchangeably herein, “treatment of cancer” and “cancer treatment” encompass a therapy that causes any of the following effects: increased inhibition of cancer progression and / or metastases, inhibition of an increase in tumor volume, reduction in tumor volume and / or growth, reduction in tumor growth rate, eradication or killing of a tumor and / or cancer cell, or any combination thereof. In some aspects, treatment can also prolong the survival of a subject, improve the prognosis and / or improve the quality of life of the subject.
[0099] “Development” or “progression” of a disease means initial manifestations and / or ensuing progression of the disease. Development of the disease can be detectable and assessed using standard clinical techniques as well known in the art. However, development also refers to progression that may be undetectable. For purpose of this disclosure, development or progression refers to the biological course of the symptoms. “Development” includes occurrence, recurrence, and onset. As used herein “onset” or “occurrence” of a target disease or disorder includes initial onset and / or recurrence.II. Compositions
[0100] In certain aspects, compositions disclosed herein may comprise at least one receptor tyrosine kinase inhibitor. In certain aspects, compositions herein comprise at least one SUMOylation inhibitor. In some aspects, compositions disclosed herein may comprise a combination of at least one RTK inhibitor and at least one SUMOylation inhibitor. In some aspects, compositions disclosed herein may be pharmaceutical compositions. In various aspects, compositions as disclosed herein exclude an ALK inhibitor.(a) Receptor Tyrosine Kinases (RTK) Inhibitors
[0101] Receptor tyrosine kinases encompass a large family of receptors that are localizedto a cell’s plasma membrane, dimerize when bound to a ligand, and have an active tyrosine kinase intracellular domain. Many tumors are characterized by disrupted RTK signaling and RTK inhibition is often a first line targeted therapy in many cancers. In various aspects, the methods herein comprise administering an RTK inhibitor.
[0102] In certain aspects, compositions disclosed herein may include at least one RTK inhibitor. As used herein, an “RTK inhibitor” or “RTKi” can include any biomolecule(s) that can inhibit RTK direct activity, inhibit RTK indirect activity, inhibit formation of an RTK receptor dimer, decrease expression of a RTK gene, decrease expression of a RTK protein, or any combination thereof. In some aspects, compositions having a RTK inhibitor can include any biomolecule(s) that are modulators and / or inhibitors of targets upstream or downstream of a RTK signaling cascade that would effectively inhibit the physiological outcome of RTK inhibition. In some aspects, biomolecule(s) capable of inhibiting one or more RTKs can be a peptide, an antibody, a chemical, a compound, an oligo, a nucleic acid molecule, or any combination thereof.
[0103] In various aspects, the RTK inhibitor herein may inhibit epidermal growth factor receptor (EGFR), a platelet-derived growth factor (PDGF) / Kit receptor, a vascular endothelial growth factor receptor (VEGFR), a fibroblast growth factor (FGF) receptor, a hepatocyte growth factor (HGF receptor), a mesenchymal-epithelial transition factor receptor (MET), an insulin or insulin-like growth factor (IGF) receptor, or any combination of any thereof. For example, in some aspects, the RTK inhibitor may be an EGFR inhibitor, a HER2 inhibitor, a HER3 inhibitor, a HER4 inhibitor, or a pan-HER inhibitor.
[0104] In certain aspects, RTK inhibitors for use in compositions herein can include a nucleic acid molecule. The term “nucleic acid molecule” as used herein refers to a molecule having nucleotides. The nucleic acid can be single, double, or multiple stranded and may comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof. In some aspects, a nucleic acid molecule for use herein can be a double-stranded RNA. In some other aspects a double stranded RNA suitable for use herein can be small temporal RNA, small nuclear RNA, small nucleolar RNA, short hairpin RNA, microRNA, or the like.
[0105] In certain aspects, RTK inhibitors for use in compositions herein may be a polypeptide, a protein, a peptide, a protein fragment, an antibody, or any combination thereof. As used herein, the terms “peptide,” “polypeptide,” and “protein,” refer to polymers comprised of amino acid monomers linked by amide bonds. Peptides may include the standard 20 a- amino acids that are used in protein synthesis by cells (i.e., natural amino acids), as well as non-natural amino acids (non-natural amino acids may be found in nature, but not used inprotein synthesis by cells, e.g., ornithine, citrulline, and sarcosine, or may be chemically synthesized), amino acid analogs, and peptidomimetics. In some aspects, a peptide inhibitor of a receptor tyrosine kinase may be fused at its C-terminus, its N-terminus, or both with at least one other peptide and / or polypeptide. In some aspects, the at least one other peptide or polypeptide may be a carrier peptide, allowing cell penetration of the resulting fusion peptide. As an example, a peptide inhibitor of RTK may be fused to a cell penetrating peptide (CPP). CPPs are short peptides that facilitate cellular uptake of various molecular cargo, e.g., via endocytosis. Non-limiting examples of CPP that may be suitable for use herein include Antennapedia Penetratin, HIV-1 TAT protein, pVEC Cadherin, Transportan Galanine / Mastoparan, MPG HIV-gp41 / SV40 T-antigen, Pep-1 HIV-reverse transcriptase / SV40 T-antigen, Polyarginines, MAP, R6W3, NLS, 8-lysines, ARF (1-22), Azurin-p28, and the like. As another example, a peptide inhibitor of RTK may be fused to celltargeting peptides (CTPs). CTPs are ideal carrier molecules as that bind with high affinity to overexpressed receptors on the tumor cell surface, effectively targeting a peptide inhibitor of RTK to the target tumor. CTPs can target, for example integrin receptors, epidermal growth factor receptors (EGFR), neuropeptide Y (NPY) receptors, gastrin-releasing peptide receptors (GRPR), somatostatin receptors (e.g., SSTR2), gonadotropin-releasing hormone receptors (GnRHR), vasoactive intestinal peptide (VIP) receptors, melanocortin 1 receptors (MC1 R), neurotensin receptors (e.g., NTSR1), and the like. In certain aspects, the CTP can bind to the target RTK, so that the RTK inhibiting peptide is near the receptor.
[0106] In certain aspects RTK inhibitors for use in compositions herein may be an RTK antibody. As used herein, the terms “RTK antibody” can refer to an antibody capable of binding to and / or blocking activity of a receptor tyrosine kinase (RTK). In some aspects, blocking activity may comprise blocking dimerization and / or kinase activity of the receptor. Blocking activity may also comprise blocking association of various target proteins (those that are usually substrates of the RTK) from binding to or associating with the RTK. In some aspects, antibodies acting as an inhibitor of RTK may be full-length antibodies, antigen binding fragments of full-length antibodies, Fab fragments, single chain antibodies (scFv), diabodies, triabodies, minibodies, nanobodies, single-domain antibodies, camelids, or any combination thereof. In some aspects, RTK antibodies disclosed herein may be of a suitable origin, for example, murine, rat, or human. Such antibodies may be non-naturally occurring, i.e., would not be produced in an animal without human act (e.g., immunizing such an animal with a desired antigen or fragment thereof or isolated from antibody libraries). Any of the antibodies described herein, e.g., RTK antibodies, can be either monoclonal or polyclonal. A “monoclonal antibody” refers to a homogenous antibody population and a “polyclonal antibody” refers to a heterogeneous antibody population. These two terms do not limit the source of an antibody orthe manner in which it is made. Exemplary RTK inhibitors that are antibodies comprise trastuzumab, pertuzumab, amivantamab, bevacizumab, margetuximab, necitumumab, ramucirumab, panitumumab, and cetuximab.
[0107] In certain aspects RTK inhibitors for use in compositions herein may be a compound (also referred to herein as “small molecule”). In some aspects, a RTK inhibitor compound may comprise osimertinib, imatinib, capmatinib, linsitinib, infigratinib, avapritinib, pemigatinib, ripretinib, selpercatinib, tucatinib, entrectinib, erdafitinib, pexidartinib, dacomitinib, gilteritinib, acalabrutinib, midostaurin, neratinib, cobimetinib, lenvatinib, nintedanib, afatinib, trametinib, axitinib, cabozantinib, ponatinib, regorafenib, tofacitinib, vandetanib, pazopanib, lapatinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, gefitinib, imatinib, varlinitib, infigratinib, mobocertinib, pPralsetinib, tepotinib, tivozanib, aflibercept, larotrectinib, any analog thereof, or any combination thereof.
[0108] In any of the above and foregoing examples, the RTK inhibitor may comprise osimertinib, imatinib, capmatinib, linsitinib, infigratinib, erlotinib, gefitinib, afatinib, dacomitinib, lapatinib, neratinib, varlitinib, tucatinib, trastuzumab, pertuzumab, amivantamab, bevacizumab, margetuximab, necitumumab, ramucirumab, panitumumab, and cetuximab.Targeted Cancer Therapy Compositions comprising RTK Inhibitors
[0109] In various aspects, compositions provided herein comprise a targeted RTK inhibitor designed to treat a certain cancer. In many aspects, the RTK inhibitor is a standard line of treatment for the given cancer. In further aspects, the RTK inhibitor may be used for treatment of a cancer selected from: bladder cancer, breast cancer, cervical cancer, colorectal cancer, dermatofibrosarcoma protuberans, endometrial cancer, esophageal cancer, head and neck cancer, gastrointestinal stromal tumor, giant cell tumor, kidney cancer, leukemia, liver and bile duct cancer, lung cancer, lymphoma, multiple myeloma, myelodysplastic / myeloproliferative disorders, ovarian epithelial / fallopian tube / primary peritoneal cancers, pancreatic cancer, soft tissue sarcoma, solid tumors with an NTRK gene fusion, stomach (gastric) cancer, systemic mastocytosis, and thyroid cancer. In various aspects, the RTK inhibitor is f used or treatment of a lung cancer such as non-small cell lung carcinoma.
[0110] Exemplary RTK inhibitors approved for various cancers listed above are provided below. It is noted that this list is non-exhaustive and other RTK inhibitors may be contemplated.
[0111] In some aspects, the RTK inhibitor may be used for treating bladder cancer and may comprise erdafitinib (Balversa®).
[0112] In some aspects, the RTK inhibitor may be used for treating bladder cancer and may comprise Bevacizumab (Avastin®).
[0113] In some aspects, the RTK inhibitor may be used for treating breast cancer and be selected from trastuzumab (Herceptin®), lapatinib (Tykerb®), pertuzumab (Perjeta®), ado- trastuzumab emtansine (Kadcyla®), neratinib maleate (Nerlynx®), fam-trastuzumab deruxtecan-nxki (Enhertu®), tucatinib (Tukysa®), and margetuximab-cmkb (Margenza®).
[0114] In some aspects, the RTK inhibitor may be used for treating cervical cancer and comprises bevacizumab (Avastin®).
[0115] In some aspects, the RTK inhibitor may be used for treating colorectal cancer and be selected from Cetuximab (Erbitux®), panitumumab (Vectibix®), bevacizumab (Avastin®), ziv-aflibercept (Zaltrap®), regorafenib (Stivarga®), and ramucirumab (Cyramza®). In some aspects, the RTK inhibitor may be approved for treating colorectal cancer and be selected from Cetuximab (Erbitux®), panitumumab (Vectibix®), bevacizumab (Avastin®), and ramucirumab (Cyramza®).
[0116] In some aspects, the RTK inhibitor may be used for treating dermatofibrosarcoma protuberans and comprise imatinib mesylate (Gleevec®).
[0117] In still further aspects, the RTK inhibitor may be used for treating endometrial cancer and comprise lenvatinib mesylate (Lenvima®).
[0118] In some aspects, the RTK inhibitor may be used for treating esophageal cancer: and be selected from Trastuzumab (Herceptin), ramucirumab (Cyramza®), fam-trastuzumab deruxtecan-nxki (Enhertu®).
[0119] In some aspects, the RTK inhibitor may be used for treating head and neck cancer and comprise Cetuximab (Erbitux®).
[0120] In some aspects, the RTK inhibitor may be used for treating gastrointestinal stromal tumor and be selected from imatinib mesylate (Gleevec®), sunitinib (Sutent®), regorafenib (Stivarga®), avapritinib (Ayvakit®), and ripretinib (Qinlock®).
[0121] In some aspects, the RTK inhibitor may be used for treating giant cell tumor and comprise Pexidartinib (Turalio®).
[0122] In some aspects, the RTK inhibitor may be used for treating kidney cancer and is selected from bevacizumab (Avastin®), sorafenib (Nexavar®), sunitinib (Sutent), pazopanib (Votrient®), axitinib (Inlyta®), cabozantinib (Cabometyx®), lenvatinib mesylate (Lenvima®), and tivozanib hydrochloride (Fotivda®). In some aspects, the RTK inhibitor may be used for treating kidney cancer and comprise Bevacizumab (Avastin®).
[0123] In some aspects, the RTK inhibitor may be used for treating leukemia and be selected from imatinib mesylate (Gleevec®), dasatinib (Sprycel®), midostaurin (Rydapt®),rituximab and hyaluronidase human (Rituxan Hycela®), gilteritinib (Xospata®), avapritinib (Ayvakit®).
[0124] In still further aspects, the RTK inhibitor may be used for treating liver and bile duct cancer and be selected from sorafenib (Nexavar®), regorafenib (Stivarga®), lenvatinib mesylate (Lenvima®), cabozantinib (Cabometyx®), ramucirumab (Cyramza®), pemigatinib (Pemazyre®), bevacizumab (Avastin®), and infigratinib phosphate (Truseltiq®). In still further aspects, the RTK inhibitor may be used for treating liver and bile duct cancer and be selected from ramucirumab (Cyramza®), and bevacizumab (Avastin®).
[0125] In still further aspects, the RTK inhibitor may be used for treating lung cancer and be selected from afatinib dimaleate (Gilotrif®), Nintedanib (Ofev®), Varlinitib (ASLAN001), Bevacizumab (Avastin®), erlotinib (Tarceva®), gefitinib (Iressa®), ramucirumab (Cyramza®), osimertinib (Tagrisso®), necitumumab (Portrazza®), dacomitinib (Vizimpro®), selpercatinib (Retevmo®), pralsetinib (Gavreto®), tepotinib hydrochloride (Tepmetko®), amivantamab- vmjw (Rybrevant®), and mobocertinib succinate (Exkivity®). For example, in some aspects the RTK inhibitor may be used for treating lung cancer and be selected from afatinib dimaleate (Gilotrif®), Nintedanib (Ofev®), Varlinitib (ASLAN001), Bevacizumab (Avastin), erlotinib (Tarceva®), gefitinib (Iressa), ramucirumab (Cyramza®), osimertinib (Tagrisso®), necitumumab (Portrazza®), dacomitinib (Vizimpro®), amivantamab-vmjw (Rybrevant®), and mobocertinib succinate (Exkivity®). In some aspects, the RTK inhibitor may be used for treating lung cancer and comprise osimertinib (Tagrisso®).
[0126] In still further aspects, the RTK inhibitor may be used for treating lymphoma and comprise rituximab and hyaluronidase human (Rituxan Hycela®).
[0127] In still further aspects, the RTK inhibitor may be used for treating multiple myeloma and comprise daratumumab and hyaluronidase-fihj (Darzalex Faspro®).
[0128] In still further aspects, the RTK inhibitor may be used for treating myelodysplastic / myeloproliferative disorders and comprise imatinib mesylate (Gleevec®).
[0129] In still further aspects, the RTK inhibitor may be used for treating ovarian epithelial / fallopian tube / primary peritoneal cancers and comprise bevacizumab (Avastin®).
[0130] In still further aspects, the RTK inhibitor may be used for treating pancreatic cancer and be selected from erlotinib (Tarceva®) and sunitinib (Sutent®). For example, the RTK inhibitor may be approved for treating pancreatic cancer and comprise erlotinib (Tarceva®).
[0131] In still further aspects, the RTK inhibitor may be used for treating soft tissue sarcoma and comprise pazopanib (Votrient®).
[0132] In still further aspects, the RTK inhibitor may be used for treating solid tumors withan NTRK gene fusion and comprise larotrectinib sulfate (Vitrakvi®).
[0133] In still further aspects, the RTK inhibitor may be used for treating stomach (gastric) cancer and be selected from trastuzumab (Herceptin), ramucirumab (Cyramza®), and famtrastuzumab deruxtecan-nxki (Enhertu®).
[0134] In still further aspects, the RTK inhibitor may be used for treating systemic mastocytosis and be selected from imatinib mesylate (Gleevec®), midostaurin (Rydapt®), and avapritinib (Ayvakit®).
[0135] In still further aspects, the RTK inhibitor may be used for treating thyroid cancer and be selected from cabozantinib (Cometriq®), vandetanib (Caprelsa®), sorafenib (Nexavar®), lenvatinib mesylate (Lenvima®), selpercatinib (Retevmo®), and pralsetinib (Gavreto®).
[0136] In certain aspects, inhibitors of RTK(s) disclosed herein can be used to treat, attenuate, or prevent tumor growth and / or progression. In certain aspects, inhibitors of RTK(s) disclosed herein can be used to treat, attenuate, or prevent tumor metastasis. In certain aspects inhibitors of RTK(s) disclosed herein can be used to treat, attenuate, or prevent treatment-resistant tumor growth and / or metastasis. In certain aspects, inhibitors of RTK(s) disclosed herein can be used to increase the therapeutic effect of one or more cancer treatments.(b) SUMOylation inhibitors
[0137] As described further herein, it has been surprisingly discovered that tumor cells treated with many receptor tyrosine kinase inhibitors display SUMOylation at the kinase site and continue to signal by converting to adaptor platforms that recruit multiple proteins and drive therapeutic resistance. Accordingly, in various aspects, the compositions herein comprise or further comprise a SUMOylation inhibitor. SUMOylation is a process in which SUMO peptides are covalently attached to specific lysine residues in target proteins, thereby regulating various aspects of protein function, including transcription, subcellular localization, DNA repair, and cell cycle. The SUMOylation pathway involves several steps including activation with E1 enzyme, conjugation with the E2 enzyme, and ligation of the SUMO peptide with cooperative activity of the E2 and E3 ligases.
[0138] As used herein, a “SUMOylation inhibitor” can include any biomolecule(s) that can inhibit SUMOylation direct activity, inhibit SUMOylation indirect activity, decrease expression of a SUMOylation gene, decrease expression of a SUMOylation enzyme, or any combination thereof. Inhibitors of SUMOylation can inhibit any of the steps of the SUMOylation pathway. In some aspects, compositions having a SUMOylation inhibitor can include any biomolecule(s) that are modulators and / or inhibitors of targets upstream or downstream of the SUMOylationpathway that would effectively inhibit the physiological outcome of SUMOylation. In some aspects, biomolecule(s) capable of inhibiting one or more SUMOylation activities may be a small molecule, peptide, an antibody, a chemical, a compound, an oligo, a nucleic acid molecule, or any combination thereof.
[0139] In some aspects a “SUMOylation inhibitor” or “SUMO inhibitor” refers to any small molecule inhibitor that binds one or more subunit of a SUMOylation enzyme, thereby inhibiting the addition of a sumo protein to a target protein. In an aspect, the small molecule inhibitor may also act of the target protein that is SUMOylated, such that ligation of the SUMO peptide is inhibited or hindered. Such small molecule inhibitors may also inhibit one or more SUMOylation enzymes. Preferred SUMOylation inhibitors have a high level of specificity to SUMO enzymes, thereby affecting SUMOylation, but do not bind or have very low level or negligible binding to proteins found in the ubiquitination pathway. Non-limiting examples of compounds that can inhibit SUMOylation include anacardic acid, 2-hydroxy-5- nitrobenzylidene thiazolidine-4-one (2-HNB), ginkgolic acid, N-ethylmaleimide (NEM), SNEP inhibitors, kerriamycin B, compound 21 , davidiin, tannic acid, ML-792, COH-OOO, TAK-981 , ML-93, GSK145A, 2-D08, spectomycin B, GN6958, SUBINs, triptolide, GN6958, momordin Ic (Me), nocardione A, dunnione, dehydrodunnione, p-lapachone, streptonigrin, ebselen, vialinin A and derivatives thereof, or any combination thereof.
[0140] In certain aspects, SUMOylation inhibitors for use in compositions herein can include a nucleic acid molecule. The term “nucleic acid molecule” as used herein refers to a molecule having nucleotides. The nucleic acid can be single, double, or multiple stranded and may comprise modified or unmodified nucleotides or non-nucleotides or various mixtures and combinations thereof. In some aspects, a nucleic acid molecule for use herein can be a double-stranded RNA. In some other aspects a double stranded RNA suitable for use herein can be small temporal RNA, small nuclear RNA, small nucleolar RNA, short hairpin RNA, microRNA, or the like.
[0141] In certain aspects, SUMOylation inhibitors for use in compositions herein may be a polypeptide, a protein, a peptide, a protein fragment, an antibody, or any combination thereof. As used herein, the terms “peptide,” “polypeptide,” and “protein,” refer to polymers comprised of amino acid monomers linked by amide bonds. Peptides may include the standard 20 a- amino acids that are used in protein synthesis by cells (i.e., natural amino acids), as well as non-natural amino acids (non-natural amino acids may be found in nature, but not used in protein synthesis by cells, e.g., ornithine, citrulline, and sarcosine, or may be chemically synthesized), amino acid analogs, and peptidomimetics. In some aspects, a peptide inhibitor of a receptor tyrosine kinase may be fused at its C-terminus, its N-terminus, or both with at least one other peptide and / or polypeptide. In some aspects, the at least one other peptideor polypeptide may be a carrier peptide, allowing cell penetration of the resulting fusion peptide. As an example, a peptide inhibitor of SUMOylation may be fused to a cell penetrating peptide (CPP). CPPs are short peptides that facilitate cellular uptake of various molecular cargo, e.g. via endocytosis. Non-limiting examples of CPP that may be suitable for use herein include antennapedia penetratin, HIV-1 TAT protein, pVEC Cadherin, transportan, galanine, mastoparan, MPG HI -gp41 / SV40 T-antigen, Pep-1 HIV-reverse transcriptase / SV40 T- antigen, polyarginines, MAP, R6W3, NLS, 8-lysines, ARF (1-22), azurin-p28, and the like. As another example, a peptide inhibitor of SUMOylation may be fused to cell-targeting peptides (CTPs). CTPs are ideal carrier molecules that bind with high affinity to overexpressed receptors on the tumor cell surface, effectively targeting a peptide inhibitor of SUMOylation to the target tumor. CTPs can target, for example integrin receptors, epidermal growth factor receptors (EGFR), neuropeptide Y (NPY) receptors, gastrin-releasing peptide receptors (GRPR), somatostatin receptors (e.g., SSTR2), gonadotropin-releasing hormone receptors (GnRHR), vasoactive intestinal peptide (VIP) receptors, melanocortin 1 receptors (MC1 R), neurotensin receptors (e.g., NTSR1), and the like. In certain aspects, the CTP can bind to the SUMOylation target, for example a RTK.
[0142] In certain aspects SUMOylation inhibitors for use in compositions herein may be an anti-SUMOylation antibody. As used herein, the terms “anti-SUMOylation antibody” can refer to an antibody capable of binding to a SUMOylation enzyme or target and / or blocking SUMOylation activity. In some aspects, blocking activity may comprise targeting of any of the SUMOylation enzymes. In some aspects, the antibodies can also target SUMOylation cites on a RTK protein. In some aspects, antibodies acting as an inhibitor of SUMOylation may be full-length antibodies, antigen binding fragments of full-length antibodies, Fab fragments, single chain antibodies (scFv), diabodies, triabodies, minibodies, nanobodies, single-domain antibodies, camelids, or any combination thereof. In some aspects, anti-SUMOylation antibodies disclosed herein may be of a suitable origin, for example, murine, rat, or human. Such antibodies are non-naturally occurring, i.e. , would not be produced in an animal without human act (e.g., immunizing such an animal with a desired antigen or fragment thereof or isolated from antibody libraries). Any of the antibodies described herein, e.g., SUMOylation antibodies, can be either monoclonal or polyclonal. A “monoclonal antibody” refers to a homogenous antibody population and a “polyclonal antibody” refers to a heterogeneous antibody population. These two terms do not limit the source of an antibody or the manner in which it is made.
[0143] In certain aspects, inhibitors of SUMOylation disclosed herein can be used to treat, attenuate, or prevent tumor growth and / or progression. In certain aspects, inhibitors of SUMOylation disclosed herein can be used to treat, attenuate, or prevent tumor metastasis.In certain aspects inhibitors of SUMOylation disclosed herein can be used to treat, attenuate, or prevent treatment-resistant tumor growth and / or metastasis. In certain aspects, inhibitors of SUMOylation disclosed herein can be used to increase the therapeutic effect of one or more cancer treatments.
[0144] In various aspects, inhibitors of SUMOylation disclosed herein can be used to increase the therapeutic effect of one or more RTK inhibitor cancer treatment. In particular aspects, inhibitors of SUMOylation disclosed herein may be used to increase the therapeutic effect of one or more EGFR inhibitor. For example, the SUMOylation inhibitor provided herein may increase the therapeutic effect of an EGFR inhibitor selected from erlotinib, gefitinib, afatinib, osimertinib, dacomitinib, lapatinib, neratinib, varlitinib, trastuzumab, pertuzumab, tucatinib, and cetuximab. In some aspects, the SUMOylation inhibitor increases the therapeutic effect of Osimertinib. As described further below, “increasing a therapeutic effect” comprises increasing sensitivity or reversing resistance to the given RTK inhibitor in a tumor, tumor cell, cancer, or cancer cell in a patient.(c) Additional Targeted Therapies
[0145] The RTK and SUMOylation inhibitors described above are types of targeted therapies - drugs or other substances that block the growth and spread of cancer by interfering with specific molecules ("molecular targets") that are involved in the growth, progression, and / or spread of cancer. Targeted cancer therapies are sometimes called "molecularly targeted drugs," "molecularly targeted therapies," "precision medicines," or similar names. Non-limiting examples of targeted therapies include hormone therapies, signal transduction inhibitors, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, toxin delivery molecules, and the like. In some aspects, additional targeted therapies may be combined with the RTK and SUMOylation inhibitors above. In some aspects, targeted therapies disclosed herein may be a small molecule, an antibody, or the like. One of skill in the art will appreciate that the appropriate targeted therapies for use herein will depend on, for example, the type of cancer, the stage of cancer, if the cancer is associated with a gene mutation, and the like. The following targeted therapies associated with one or more cancer types are non-limiting examples of suitable targeted therapies for use in the compositions and methods of the present disclosure: 1) Bladder cancer: atezolizumab (Tecentriq®), nivolumab (Opdivo®), avelumab (Bavencio®), pembrolizumab (Keytruda®), enfortumab vedotin-ejfv (Fadeev®), sacituzumab govitecan-hziy (Trodelvy®); 2) Brain cancer: everolimus (Afinitor®), belzutifan (Welireg®); 3) Breast cancer: everolimus (Afinitor®), tamoxifen (Nolvadex®), toremifene (Fareston®), fulvestrant (Faslodex®), anastrozole (Arimidex®), exemestane (Aromasin®), letrozole (Femara®), palbociclib(Ibrance®), ribociclib (Kisqali®), abemaciclib (Verzenio®), olaparib (Lynparza®), talazoparib tosylate (Talzenna®), sacituzumab govitecan-hziy (Trodelvy®), pembrolizumab (Keytruda®), 4) Cervical cancer: pembrolizumab (Keytruda®), tisotumab vedotin-tftv (Tivdak®); 5) Colorectal cancer: nivolumab (Opdivo®), ipilimumab (Yervoy®), encorafenib (Braftovi®), pembrolizumab (Keytruda®); 6) Endometrial cancer: pembrolizumab (Keytruda®), dostarlimab-gxly (Jemperli®); 7) Esophageal cancer: pembrolizumab (Keytruda®), nivolumab (Opdivo®), 8) Head and neck cancer: pembrolizumab (Keytruda®), nivolumab (Opdivo®);9) Giant cell tumor: denosumab (Xgeva®), pexidartinib hydrochloride (Turalio®); 10) Kidney cancer: temsirolimus (Torisel®), everolimus (Afinitor®), nivolumab (Opdivo®), ipilimumab (Yervoy®), pembrolizumab (Keytruda®), avelumab (Bavencio®), belzutifan (Welireg®); 11) Leukemia: tretinoin (Vesanoid®), nilotinib (Tasigna®), bosutinib (Bosulif®), rituximab (Rituxan®), alemtuzumab (Campath®), ofatumumab (Arzerra®), obinutuzumab (Gazyva®), ibrutinib (Imbruvica®), idelalisib (Zydelig®), blinatumomab (Blincyto®), venetoclax (Venclexta®), ponatinib hydrochloride (Iclusig®), enasidenib mesylate (Idhifa®), inotuzumab ozogamicin (Besponsa®), tisagenlecleucel (Kymriah®), gemtuzumab ozogamicin (Mylotarg®), ivosidenib (Tibsovo®), duvelisib (Copiktra®), moxetumomab pasudotox-tdfk (Lumoxiti®), glasdegib maleate (Daurismo®), tagraxofusp-erzs (Elzonris®), acalabrutinib (Calquence®), brexucabtagene autoleucel (Tecartus®), asciminib hydrochloride (Scemblix®); 12) Liver and bile duct cancer: nivolumab (Opdivo®), pembrolizumab (Keytruda®), ipilimumab (Yervoy®), atezolizumab (Tecentriq®), ivosidenib (Tibsovo®); 13) Lung cancer: nivolumab (Opdivo®), pembrolizumab (Keytruda®), atezolizumab (Tecentriq®), trametinib (Mekinist®), dabrafenib (Tafinlar®), durvalumab (Imfinzi®), capmatinib hydrochloride (Tabrecta®), ipilimumab (Yervoy®), cemiplimab-rwlc (Libtayo®), sotorasib (Lumakras®), 14) Lymphoma: ibritumomab tiuxetan (Zevalin®), denileukin diftitox (Ontak®), brentuximab vedotin (Adcetris®), rituximab (Rituxan®), vorinostat (Zolinza®), romidepsin (Istodax®), bexarotene (Targretin®), bortezomib (Velcade®), pralatrexate (Folotyn®), ibrutinib (Imbruvica®), siltuximab (Sylvant®), belinostat (Beleodaq®), obinutuzumab (Gazyva®), nivolumab (Opdivo®), pembrolizumab (Keytruda®), copanlisib hydrochloride (Aliqopa®), axicabtagene ciloleucel (Yescarta®), acalabrutinib (Calquence®), tisagenlecleucel (Kymriah®), venetoclax (Venclexta®), mogamulizumab-kpkc (Poteligeo®), duvelisib (Copiktra®), polatuzumab vedotin-piiq (Polivy®), zanubrutinib (Brukinsa®), tazemetostat hydrobromide (Tazverik®), selinexor (Xpovio®), tafasitamab-cxix (Monjuvi®), brexucabtagene autoleucel (Tecartus®), umbralisib tosylate (Ukoniq®), lisocabtagene maraleucel (Breyanzi®), loncastuximab tesirine-lpyl (Zynlonta®); 15) Multiple myeloma: bortezomib (Velcade®), carfilzomib (Kyprolis®), daratumumab (Darzalex®), ixazomib citrate (Ninlaro®), elotuzumab (Empliciti®), selinexor (Xpovio®), isatuximab-irfc (Sarclisa®), belantamab mafodotin-blmf (Blenrep®), idecabtagene vicleucel (Abecma®), ciltacabtageneautoleucel (Carvykti®); 16) Myelodysplastic / myeloproliferative disorders: ruxolitinib phosphate (Jakafi®), fedratinib hydrochloride (Inrebic®), pacritinib citrate (Vonjo®); 17) Ovarian epithelial / fallopian tube / primary peritoneal cancers: olaparib (Lynparza®), rucaparib camsylate (Rubraca®), niraparib tosylate monohydrate (Zejula®); 18) Pancreatic cancer: everolimus (Afinitor®), olaparib (Lynparza®), belzutifan (Welireg®); 19) Soft tissue sarcoma: alitretinoin (Panretin®), tazemetostat hydrobromide (Tazverik®), sirolimus proteinbound particles (Fyarro®); 20) Stomach (gastric) cancer: pembrolizumab (Keytruda®), nivolumab (Opdivo®); 21) Thyroid cancer: trametinib (Mekinist®), dabrafenib (Tafinlar®).
[0146] The present disclosure can provide for use of one or more anticancer therapies in combination with any of the compositions disclosed herein. In accordance with some aspects of the disclosure, the one or more anticancer therapies may be prescribed to a subject with increased likelihood of RTK inhibitor resistance or may be used and / or administered to treat a cancer, a solid tumor, a metastasis, or any other cancerous condition characterized by RTK inhibitor resistance. In some aspects, one or more anticancer therapies may be any one or more of surgery, radiation, chemotherapy, immunotherapy, vaccine or combinations thereof.
[0147] In some aspects, the one or more anticancer therapies may be chemotherapy. Chemotherapeutic agents may be selected from any one or more of cytotoxic antibiotics, antimetabolities, anti-mitotic agents, alkylating agents, arsenic compounds, DNA topoisomerase inhibitors, taxanes, nucleoside analogues, plant alkaloids, and toxins; and synthetic derivatives thereof. Exemplary compounds include, but are not limited to, alkylating agents: treosulfan, and trofosfamide; plant alkaloids: vinblastine, paclitaxel, docetaxol; DNA topoisomerase inhibitors: doxorubicin, epirubicin, etoposide, camptothecin, topotecan, irinotecan, teniposide, crisnatol, and mitomycin; anti-folates: methotrexate, mycophenolic acid, and hydroxyurea; pyrimidine analogs: 5-fluorouracil, doxifluridine, and cytosine arabinoside; purine analogs: mercaptopurine and thioguanine; DNA antimetabolites: 2'-deoxy- 5-fluorouridine, aphidicolin glycinate, and pyrazoloimidazole; and antimitotic agents: halichondrin, colchicine, and rhizoxin. Compositions comprising one or more chemotherapeutic agents (e.g., FLAG, CHOP) may also be used. FLAG comprises fludarabine, cytosine arabinoside (Ara-C) and G-CSF. CHOP comprises cyclophosphamide, vincristine, doxorubicin, and prednisone. In another aspects, PARP (e.g., PARP-1 and / or PARP-2) inhibitors are used and such inhibitors are well known in the art (e.g., Olaparib, ABT- 888, BSI-201 , BGP-15, INO-1001 , PJ34, 3-aminobenzamide, 4-amino-1 ,8-naphthalimide, 6(5H)-phenanthridinone, benzamide, NU1025).
[0148] In some aspects, the one or more anticancer therapies may be radiation therapy. The radiation used in radiation therapy can be ionizing radiation. Radiation therapy can also be gamma rays, X-rays, or proton beams. Examples of radiation therapy include, but are notlimited to, external-beam radiation therapy, interstitial implantation of radioisotopes (1-125, palladium, iridium), radioisotopes such as strontium-89, thoracic radiation therapy, intraperitoneal P-32 radiation therapy, and / or total abdominal and pelvic radiation therapy. In some aspects, the radiation therapy can be administered as external beam radiation or teletherapy wherein the radiation is directed from a remote source. In other aspects, the radiation treatment can also be administered as internal therapy or brachytherapy wherein a radioactive source is placed inside the body close to cancer cells or a tumor mass. Also encompassed is the use of photodynamic therapy comprising the administration of photosensitizers, such as hematoporphyrin and its derivatives, vertoporfin (BPD-MA), phthalocyanine, photosensitizer Pc4, demethoxy-hypocrellin A and 2BA-2-DMHA.
[0149] In some aspects, the one or more anticancer therapies may be immunotherapy. Immunotherapy may comprise, for example, use of cancer vaccines and / or sensitized antigen presenting cells. The immunotherapy can involve passive immunity for short-term protection of a host, achieved by the administration of a pre-formed antibody directed against a cancer antigen or disease antigen (e.g., administration of a monoclonal antibody, optionally linked to a chemotherapeutic agent or toxin, to a tumor antigen). Immunotherapy can also focus on using the cytotoxic lymphocyte-recognized epitopes of cancer cell lines.
[0150] In some aspects, the one or more anticancer therapies may be hormonal therapy, Hormonal therapeutic treatments can comprise, for example, hormonal agonists, hormonal antagonists (e.g., flutamide, bicalutamide, tamoxifen, raloxifene, leuprolide acetate (LLIPRON), LH-RH antagonists), inhibitors of hormone biosynthesis and processing, steroids (e.g., dexamethasone, retinoids, deltoids, betamethasone, cortisol, cortisone, prednisone, dehydrotestosterone, glucocorticoids, mineralocorticoids, estrogen, testosterone, progestins), vitamin A derivatives (e.g., all-trans retinoic acid (ATRA)); vitamin D3 analogs; antigestagens (e.g., mifepristone, onapristone), or antiandrogens (e.g., cyproterone acetate).
[0151] In certain aspects, the duration and / or dose of treatment with anticancer therapies may vary according to the particular anti-cancer agent or combination thereof. An appropriate treatment time for a particular cancer therapeutic agent will be appreciated by the skilled artisan. In some aspects, the continued assessment of optimal treatment schedules for each cancer therapeutic agent is contemplated, where the genetic signature of the cancer of the subject as determined by the methods of the disclosure is a factor in determining optimal treatment doses and schedules.(d) Pharmaceutical Formulations and Treatment Regimens
[0152] In certain aspects, any one or more active agents disclosed herein (i.e., RTK inhibitor, SUMOylation inhibitor, or any combination thereof) may be provided per se or as partof a pharmaceutical composition, where the active agent(s) can be mixed with suitable carriers or excipients.
[0153] As used herein a “pharmaceutical composition” refers to a preparation of one or more of the active ingredients described herein with other chemical components such as physiologically suitable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.(i) Pharmaceutically acceptable carriers and excipients
[0154] Hereinafter, the phrases “physiologically acceptable carrier” and “pharmaceutically acceptable carrier” are interchangeably used herein to refer to a carrier or a diluent that does not cause significant irritation to an organism and does not abrogate the biological activity and properties of the administered compound. An adjuvant is included under these phrases.
[0155] In certain aspects, compositions disclosed herein may further compromise one or more pharmaceutically acceptable diluent(s), excipient(s), and / or carrier(s). As used herein, a pharmaceutically acceptable diluent, excipient, or carrier, refers to a material suitable for administration to a subject without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained. Pharmaceutically acceptable diluents, carriers, and excipients can include, but are not limited to, physiological saline, Ringer’s solution, phosphate solution or buffer, buffered saline, and other carriers known in the art.
[0156] In some aspects, pharmaceutical compositions herein may also include stabilizers, anti-oxidants, colorants, other medicinal or pharmaceutical agents, carriers, adjuvants, preserving agents, stabilizing agents, wetting agents, emulsifying agents, solution promoters, salts, solubilizers, antifoaming agents, antioxidants, dispersing agents, surfactants, or any combination thereof. Herein, the term “excipient” refers to an inert substance added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples, without limitation, of excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils and polyethylene glycols. Techniques for formulation and administration of drugs may be found in “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, Pa., latest edition, which is incorporated herein by reference.
[0157] In certain aspects, pharmaceutical compositions described herein may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries to facilitate processing of genetically modified endothelial progenitor cells into preparations which can be used pharmaceutically. In some aspects, any of the well- known techniques, carriers, and excipients may be used as suitable and / or as understood inthe art.
[0158] In certain aspects, pharmaceutical compositions described herein may be an aqueous suspension comprising one or more polymers as suspending agents. Such polymers may include, by way of example and without limitation, water-soluble polymers such as cellulosic polymers, e.g., hydroxypropyl methylcellulose; water-insoluble polymers such as cross-linked carboxyl-containing polymers; mucoadhesive polymers, selected from, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methylmethacrylate), polyacrylamide, polycarbophil, acrylic acid / butyl acrylate copolymer, sodium alginate, and dextran; and others known to those of skill in the art. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% total amount of polymers as suspending agent(s) by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of polymers as suspending agent(s) by total weight of the composition.
[0159] In certain aspects, pharmaceutical compositions disclosed herein may comprise a viscous formulation. In some aspects, viscosity of composition herein may be increased by the addition of one or more gelling or thickening agents. In some aspects, compositions disclosed herein may comprise one or more gelling or thickening agents in an amount to provide a sufficiently viscous formulation to remain on treated tissue. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% total amount of gelling or thickening agent(s) by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of gelling or thickening agent(s) by total weight of the composition. Thickening agents may include, by way of example and without limitation, hydroxypropyl methylcellulose, hydroxyethyl cellulose, polyvinylpyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium chondroitin sulfate, sodium hyaluronate. Viscosity enhancing agents may include, by way of example and without limitation acacia (gum arabic), agar, aluminum magnesium silicate, sodium alginate, sodium stearate, bladderwrack, bentonite, carbomer, carrageenan, carbopol, xanthan, cellulose, microcrystalline cellulose (MCC), ceratonia, chitin, carboxymethylated chitosan, chondrus, dextrose, furcellaran, gelatin, ghatti gum, guar gum, hectorite, lactose, sucrose, maltodextrin, mannitol, sorbitol, honey, maize starch, wheat starch, rice starch, potato starch, gelatin, sterculia gum, xanthum gum, gum tragacanth, ethyl cellulose, ethylhydroxyethyl cellulose, ethylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose,hydroxypropyl cellulose, poly(hydroxyethyl methacrylate), oxypolygelatin, pectin, polygeline, povidone, propylene carbonate, methyl vinyl ether / maleic anhydride copolymer (PVM / MA), poly(methoxyethyl methacrylate), poly(methoxyethoxyethyl methacrylate), hydroxypropyl cellulose, hydroxypropylmethyl-cellulose (HPMC), sodium carboxymethyl-cellulose (CMC), silicon dioxide, polyvinylpyrrolidone (PVP: povidone), Splenda® (dextrose, maltodextrin and sucralose), and others known to those of skill in the art.
[0160] In certain aspects, pharmaceutical compositions disclosed herein may comprise additional agents or additives selected from a group including surface-active agents, detergents, solvents, acidifying agents, alkalizing agents, buffering agents, tonicity modifying agents, ionic additives effective to increase the ionic strength of the solution, antimicrobial agents, antibiotic agents, antifungal agents, antioxidants, preservatives, electrolytes, antifoaming agents, oils, stabilizers, enhancing agents, and the like. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% total amount of one or more agents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more agents by total weight of the composition. In some aspects, one or more of these agents may be added to improve the performance, efficacy, safety, shelf-life and / or other property of the muscarinic antagonist composition of the present disclosure. In some aspects, additives may be biocompatible, without being harsh, abrasive, and / or allergenic.
[0161] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more acidifying agents. As used herein, “acidifying agents” refers to compounds used to provide an acidic medium. Such compounds include, by way of example and without limitation, acetic acid, amino acid, citric acid, fumaric acid and other alpha hydroxy acids, such as hydrochloric acid, ascorbic acid, and nitric acid and others known to those of skill in the art. In some aspects, any pharmaceutically acceptable organic or inorganic acid may be used. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% total amount of one or more acidifying agents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more acidifying agents by total weight of the composition.
[0162] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more alkalizing agents. As used herein, “alkalizing agents” are compounds used to provide alkaline medium. Such compounds include, by way of example and without limitation,ammonia solution, ammonium carbonate, diethanolamine, monoethanolamine, potassium hydroxide, sodium borate, sodium carbonate, sodium bicarbonate, sodium hydroxide, triethanolamine, and trolamine and others known to those of skill in the art. In some aspects, any pharmaceutically acceptable organic or inorganic base can be used. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% total amount of one or more alkalizing agents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more alkalizing agents by total weight of the composition.
[0163] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more antioxidants. As used herein, “antioxidants” are agents that inhibit oxidation and thus can be used to prevent the deterioration of preparations by the oxidative process. Such compounds include, by way of example and without limitation, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophophorous acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite and others known to those of skill in the art. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% total amount of one or more antioxidants by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more antioxidants by total weight of the composition.
[0164] In certain aspects, pharmaceutical compositions disclosed herein may comprise a buffer system. As used herein, a “buffer system” is a composition comprised of one or more buffering agents wherein “buffering agents” are compounds used to resist change in pH upon dilution or addition of acid or alkali. Buffering agents include, by way of example and without limitation, potassium metaphosphate, potassium phosphate, monobasic sodium acetate and sodium citrate anhydrous and dihydrate and others known to one of ordinary skill in the art. In some aspects, any pharmaceutically acceptable organic or inorganic buffer can be used. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% total amount of one or more buffering agents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more buffering agents by total weight of the composition.
[0165] In some aspects, the amount of one or more buffering agents may depend on the desired pH level of a composition. In some aspects, pharmaceutical compositions disclosed herein may have a pH of about 6 to about 9. In some aspects, pharmaceutical compositions disclosed herein may have a pH greater than about 8, greater than about 7.5, greater than about 7, greater than about 6.5, or greater than about 6.
[0166] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more preservatives. As used herein, “preservatives” refers to agents or combination of agents that inhibits, reduces or eliminates bacterial growth in a pharmaceutical dosage form. Suitable preservatives are known in the art. . In some aspects, any pharmaceutically acceptable preservative can be used. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% total amount of one or more preservatives by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more preservatives by total weight of the composition.
[0167] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more surface- acting reagents or detergents. In some aspects, surface-acting reagents or detergents may be synthetic, natural, or semi-synthetic. Such compounds include, by way of example and without limitation, anionic detergents, cationic detergents, zwitterionic detergents, ampholytic detergents, amphoteric detergents, nonionic detergents having a steroid skeleton, and others known to those of skill in the art. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% total amount of one or more surface-acting reagents or detergents by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more surfaceacting reagents or detergents by total weight of the composition.
[0168] In certain aspects, pharmaceutical compositions disclosed herein may comprise one or more stabilizers. As used herein, a “stabilizer” refers to a compound used to stabilize an active agent against physical, chemical, or biochemical process that would otherwise reduce the therapeutic activity of the agent. Suitable stabilizers include, by way of example and without limitation, succinic anhydride, albumin, sialic acid, creatinine, glycine and other amino acids, niacinamide, sodium acetyltryptophonate, zinc oxide, sucrose, glucose, lactose, sorbitol, mannitol, glycerol, polyethylene glycols, sodium caprylate and sodium saccharin and others known to those of skill in the art. In some aspects, pharmaceutical compositionsdisclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% total amount of one or more stabilizers by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more stabilizers by total weight of the composition.
[0169] In some aspects, pharmaceutical compositions disclosed herein may comprise one or more tonicity agents. As used herein, a “tonicity agents” refers to a compound that can be used to adjust the tonicity of the liquid formulation. Suitable tonicity agents include, but are not limited to, glycerin, lactose, mannitol, dextrose, sodium chloride, sodium sulfate, sorbitol, trehalose, and others known to those of skill in the art. Osmolarity in a composition may be expressed in milliosmoles per liter (mOsm / L). Osmolarity may be measured using methods commonly known in the art. In some aspects, a vapor pressure depression method is used to calculate the osmolarity of the compositions disclosed herein. In some aspects, the amount of one or more tonicity agents comprising a pharmaceutical composition disclosed herein may result in a composition osmolarity of about 150 mOsm / L to about 500 mOsm / L, about 250 mOsm / L to about 500 mOsm / L, about 250 mOsm / L to about 350 mOsm / L, about 280 mOsm / L to about 370 mOsm / L or about 250 mOsm / L to about 320 mOsm / L. In some aspects, a composition herein may have an osmolality ranging from about 100 mOsm / kg to about 1000 mOsm / kg, from about 200 mOsm / kg to about 800 mOsm / kg, from about 250 mOsm / kg to about 500 mOsm / kg, or from about 250 mOsm / kg to about 320 mOsm / kg, or from about 250 mOsm / kg to about 350 mOsm / kg or from about 280 mOsm / kg to about 320 mOsm / kg. In some aspects, a pharmaceutical composition described herein may have an osmolarity of about 100 mOsm / L to about 1000 mOsm / L, about 200 mOsm / L to about 800 mOsm / L, about 250 mOsm / L to about 500 mOsm / L, about 250 mOsm / L to about 350 mOsm / L, about 250 mOsm / L to about 320 mOsm / L, or about 280 mOsm / L to about 320 mOsm / L. In some aspects, pharmaceutical compositions disclosed herein may comprise at least 5%, at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50% total amount of one or more tonicity modifiers by total weight of the composition. In some aspects, pharmaceutical compositions disclosed herein may comprise about 5% to about 99%, about 10%, about 95%, or about 15% to about 90% total amount of one or more tonicity modifiers by total weight of the composition.(ii) Dosage formulations
[0170] In certain aspects, the present disclosure provides compositions formulated for one or more routes of administration. Suitable routes of administration may, for example, include oral, rectal, transmucosal, transnasal, intestinal, and / or parenteral delivery. In some aspects, compositions herein formulated can be formulated for parenteral delivery. In some aspects,compositions herein formulated can be formulated intramuscular, subcutaneous, intramedullary, intravenous, intraperitoneal, and / or intranasal injections.
[0171] In certain aspects, one may administer a composition herein in a local or systemic manner, for example, via local injection of the pharmaceutical composition directly into a tissue region of a patient. In some aspects, a pharmaceutical composition disclosed herein can be administered parenterally, e.g., by intravenous injection, intracerebroventricular injection, intra-cisterna magna injection, intra-parenchymal injection, or any combination thereof. In some aspects, a pharmaceutical composition disclosed herein can administered to subject as disclosed herein. In some aspects, a pharmaceutical composition disclosed herein can administered to human patient. In some aspects, a pharmaceutical composition disclosed herein can administered to a human patient via at least two administration routes. In some aspects, the combination of administration routes by be intracerebroventricular injection and intravenous injection; intrathecal injection and intravenous injection; intra-cisterna magna injection and intravenous injection; and / or intra-parenchymal injection and intravenous injection.
[0172] In certain aspects, pharmaceutical compositions of the present disclosure may be manufactured by processes well known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.
[0173] In certain aspects, pharmaceutical compositions for use in accordance with the present disclosure thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active ingredients into preparations which, can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen. For injection, the active ingredients of a pharmaceutical composition herein may be formulated in aqueous solutions, preferably in physiologically compatible buffers. Such buffers may include, but are not limited to, Hank's solution, Ringer's solution, physiological salt buffer, and others known to those of skill in the art.
[0174] In certain aspects, pharmaceutical compositions described herein may be formulated for parenteral administration, e.g., by bolus injection or continuous infusion. Formulations for injection herein may be presented in unit dosage form, e.g., in ampoules or in multidose containers with optionally, an added preservative. In some aspects, compositions herein may be suspensions, solutions, or emulsions in oily or aqueous vehicles, and / or may contain formulatory agents such as suspending, stabilizing, and / or dispersing agents.
[0175] In certain aspects, pharmaceutical compositions herein formulated for parenteraladministration may include aqueous solutions of the active preparation in water-soluble form. In some aspects, compositions herein comprising suspensions of the active preparation may be prepared as oily or water-based injection suspensions. Suitable lipophilic solvents and / or vehicles for use herein may include, but are not limited to, fatty oils such as sesame oil, or synthetic fatty acids esters such as ethyl oleate, triglycerides, or liposomes, and others known to those of skill in the art. In some aspects, compositions herein comprising aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as, but are not limited to, sodium carboxymethyl cellulose, sorbitol, dextran, and others known to those or ordinary skill in the art. In some aspects, compositions herein comprising a suspension may also contain one or more suitable stabilizers and / or agents which increase the solubility of the active ingredients (e.g., RTK inhibitor or SUMOylation inhibitor) to allow for the preparation of highly concentrated solutions.
[0176] In some aspects, compositions herein may comprise the active ingredient in a powder form for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water-based solution, before use.
[0177] Pharmaceutical compositions suitable for use in context of the present disclosure may include compositions wherein the active ingredients can be contained in an amount effective to achieve the intended purpose. In some aspects, a therapeutically effective amount means an amount of active ingredients effective to prevent, slow, alleviate or ameliorate symptoms of a disorder (e.g., cancer) or prolong the survival of the subject being treated.
[0178] Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
[0179] For any preparation used in the methods of the present disclosure, the therapeutically effective amount or dose can be estimated initially from in vitro and cell culture assays and or screening platforms disclosed herein. For example, a dose can be formulated in animal models to achieve a desired concentration or titer. Such information can be used to more accurately determine useful doses in humans.
[0180] In some aspects, toxicity and therapeutic efficacy of the active ingredients disclosed herein can be determined by standard pharmaceutical procedures in vitro, in cell cultures or experimental animals. In some aspects, data obtained from these in vitro and cell culture assays and animal studies can be used in formulating a range of dosage for use in a human subject. In some aspects, a dosage for use herein may vary depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition.
[0181] In certain aspects, dosage amounts and / or dosing intervals may be adjusted individually to brain or blood levels of the active ingredient that are sufficient to induce or suppress the biological effect (minimal effective concentration, MEC). In some aspects, the MEC for an active ingredient (e.g., RTK inhibitor or SUMOylation inhibitor) may vary for each preparation but can be estimated from in vitro data. In some aspects, dosages necessary to achieve the MEC herein may depend on individual characteristics and route of administration. Detection assays can be used to determine plasma concentrations.
[0182] In certain aspects, depending on the severity and responsiveness of the condition to be treated, dosing with compositions herein can be of a single or a plurality of administrations, with course of treatment lasting from several days to several weeks or until cure is effected or diminution of the disease state is achieved.
[0183] In certain aspects, amounts of a composition herein to be administered will be dependent on the subject being treated, the severity of the affliction, the manner of administration, the judgment of the prescribing physician, and the like. In some aspects, effective doses may be extrapolated from dose-responsive curves derived from in vitro or in vivo test systems.III. Methods of Use
[0184] The present disclosure provides for methods for improving sensitivity and / or preventing resistance of cancer cells to an RTK inhibitor, either in vitro or in vivo.
[0185] Accordingly, in one aspect, the disclosure provides for a method of increasing sensitivity of a cancer cell to a receptor tyrosine kinase inhibitor (RTK inhibitor) - including but not limited to an RTK inhibitor described above. In various aspects, the methods comprise contacting a cancer cell with at least one SUMOylation inhibitor (e.g., an SUMOylation inhibitor described above) wherein contacting the cell with the at least one SUMOylation inhibitor increases the cell’s sensitivity to an RTK inhibitor as compared to a cell not contacted with the SUMOylation inhibitor. In various aspects, the cell survival of the cancer cell is decreased after contacting the cancer cell with at least one SUMOylation inhibitor. In further aspects, the cell proliferation of the cancer cell is decreased after contacting the cancer cell with at least one SUMOylation inhibitor. In any of these aspects, the cancer cell may be located in or obtained from a lung tumor, a breast tumor, a pancreatic tumor, a colorectal tumor, an esophageal tumor, a head-and-neck tumor, a hematological malignancy, a brain tumor, an ovarian tumor, a stomach tumor, a gastric tumor, a prostate tumor, a thyroid tumor, bladder tumor, a lymphoma, melanoma, or a kidney tumor. In various aspects, the cell is in vitro or is in vivo. When the cell is in vivo the method may have therapeutic benefits and may be applied to treat, attenuate, and / or prevent cancer in a subject. In various aspects, methods of increasingsensitivity of a cancer cell as disclosed herein exclude use of, e.g., contacting a cancer cell with an ALK inhibitor.
[0186] Therefore, in various aspects, the disclosure provides for methods of treating, attenuating, and preventing cancer in a subject in need thereof. The present disclosure also provides for methods of impairing tumor growth compared to tumor growth in an untreated subject with identical disease condition and predicted outcome. In certain aspects, a method for treating, attenuating, or preventing tumor growth or a method for treating, attenuating, or preventing a cancer and / or metastasis in a subject can generally comprise increasing sensitivity of a cancer cell in the subject to a targeted therapy targeting receptor tyrosine kinase signaling (e.g., sensitivity to an RTK inhibitor).
[0187] In some aspects, a method for treating, attenuating and / or preventing cancer in a subject in need thereof may comprise administering to the subject in need thereof (a) at least one receptor tyrosine kinase (RTK) inhibitor as provided herein, and (b) at least one SUMOylation inhibitor as provided herein. In various aspects, methods of treating, attenuating and / or preventing cancer in a subject in need thereof as disclosed herein exclude administering an ALK inhibitor.
[0188] In various aspects, a method for treating a tumor in a subject in need thereof is provided, the method comprising: administering to the subject at least one SUMOylation inhibitor as provided herein, wherein the subject has undergone, is undergoing or will undergo an anti-cancer therapy comprising one or more targeted receptor tyrosine kinase (RTK) inhibitors, as provided herein.
[0189] Still other aspects are directed to methods of preventing sensitization and / or resistance to an anti-cancer therapy comprising a receptor tyrosine kinase (RTK) inhibitor, the methods comprising administering to a subject in need thereof, a SUMOylation inhibitor prior to or concurrent with the anti-cancer therapy comprising the RTK inhibitor. In some aspects disclosed herein, compositions and methods disclosed herein are designed to re-sensitize or sensitize a tumor in a subject to RTK inhibition to reduce costs, improve outcome, and reduce or eliminate patient exposure to an anticancer therapy without significant effect. As noted, suitable RTK inhibitors and SUMOylation inhibitors that may be used in the methods herein are described above.(a) Malignant Tumors
[0190] In any of these aspects, the compositions and methods herein are directed to treating a malignant tumor in a subject. In various aspects, the malignant tumor may be resistant to an RTK inhibitor (RTKi) or be at risk of developing resistance to the RTKi. In some aspects the malignant tumor comprises a solid tumor or a non-solid tumor. In some aspects, the malignanttumor comprises a carcinoma, a sarcoma, a hematological malignancy, or any combination thereof.
[0191] In some aspects, the malignant tumor is a solid tumor. In some aspects, a solid tumor can be an abnormal mass of tissue that is devoid of cysts or liquid regions within the tumor. In some aspects, a solid tumor herein can be a malignant cancer that has metastasized. In other aspects, solid tumors contemplated herein can include, but are not limited to, sarcomas, carcinomas, lymphomas, gliomas, or any combinational thereof. In accordance with some aspects herein, malignant tumors can include, but are not limited to, lung tumor, a breast tumor, a pancreatic tumor, a colorectal tumor, an esophageal tumor, a head-and-neck tumor, a brain tumor, an ovarian tumor, a stomach tumor, a gastric tumor, a prostate tumor, a thyroid tumor, bladder tumor, melanoma, a kidney tumor, a soft tissue sarcoma, a urothelial carcinoma, a cervical tumor, a liver tumor, an endometrial tumor, a solid tumor with an NTRK gene fusion, systemic mastocytosis, or any combination thereof. In some aspects, a targeted tumor contemplated herein can include a solid tumor such as non-small-cell lung cancer (NSCLC), HER-2 positive breast cancer, glioblastoma, gastrointestinal stromal tumor, esophageal tumor, liver tumor, bladder tumor or any combination thereof.
[0192] In some aspects, the malignant tumor (e.g., that is resistant or suspected of becoming resistant to RTKi) is a hematological malignancy. As used herein a “hematological malignancy” refer to a tumor that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies: leukemia, lymphoma and multiple myeloma. The hematological malignancy may be a solid tumor or a non-solid tumor. In some aspects, the hematological malignancy is a leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL) or hairy cell leukemia). In some aspects, the hematological malignancy is a lymphoma (e.g., a Hodgkin’s lymphoma such as nodular sclerosis class HL (NSHL), a mixed cellularity classic HL (MCHL), a lymphocyte rich classic HL (LRHL) or a lymphocyte depleted classic HL (LDHL) or a nonHodgkin’s lymphoma such as a B-cell neoplasm or a T-cell or putative NK-cell neoplasm). In other aspects, the hematological malignancy is multiple myeloma.
[0193] Accordingly, in various aspects, the malignant tumor may comprise a lung tumor, a breast tumor, a pancreatic tumor, a colorectal tumor, an esophageal tumor, a head-and-neck tumor, a hematological malignancy, a brain tumor, an ovarian tumor, a stomach tumor, a gastric tumor, a gastrointestinal stromal tumor, a prostate tumor, a thyroid tumor, bladder tumor, dermatofibrosarcoma protuberans, a giant cell tumor, a lymphoma, melanoma, a myeloma, a kidney tumor, a soft tissue sarcoma, chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), urothelial carcinoma, a cervical tumor, liver or bile duct tumor,endometrial tumor or any combination thereof. In certain aspects, the malignant tumor can be derived from a non-small-cell lung cancer (NSCLC), HER-2 positive breast cancer, glioblastoma, gastrointestinal stromal tumor, esophageal tumor, liver or bile duct tumor, bladder tumor or any combination thereof.
[0194] In various aspects, the malignant tumor is a candidate for a targeted therapy targeting aberrant receptor tyrosine kinase signaling. For example, the malignant tumor may comprise one or more somatic mutations, translocations, amplifications and / or other disruptions in a gene encoding a receptor tyrosine kinase (RTK). In aspects, the somatic mutations, translocations, amplifications and / or other disruptions occur in a gene for an RTK. In various aspects, the at least one gene encoding a RTK comprises an EGFR gene, HER2 gene, HER3 gene, HER4 gene, c-Met gene, ROS1 gene, IGF-1R gene, TRKA gene, TRKB gene, TRKC gene, a PDGFR gene, a VEGFR gene, a FGFR gene, a FLT3 gene, a NTRK gene, a RET gene or any combination thereof. In various aspects, the malignant tumor has excessive RTK signaling that may be caused, for example, by the one or more somatic mutations, translocations, amplifications and / or other disruptions in a gene encoding the RTK. For example, the tumor may express one or more hyperactive or overactive RTKs. In some aspects, the malignant tumor has aberrant (i.e., excessive) RTK signaling caused by a different pathway (e.g., not caused by a direct mutation in an RTK gene) but is still considered a candidate for RTK inhibition. In any of these aspects, the receptor tyrosine kinase that is hyperactive, overactive, or that is involved in excessive RTK signaling comprises EGFR, HER2, HER3, HER4, c-Met, ROS1 , IGF-1 R, TRKA, TRKB, TRKC, PDGFR, VEGFR, FGFR, FLT3, NTRK, or RET.
[0195] In still further aspects, the malignant tumor is at high risk for resistance to RTK inhibition. In some aspects, the tumor is refractory. As used herein, “refractory” refers to the tumor that does not respond to or becomes resistant to a treatment. In some aspects, the subject herein may have a tumor that is resistant to at least one targeted therapy. In some aspects, the subject herein may have a tumor that is resistant or is at high risk of becoming resistant to RTK inhibition. In some aspects, the subject may be a human patient having a relapsed disease. As used herein, “relapsed” or “relapses” refers to a tumor that returns or progresses following a period of improvement (e.g., a partial or complete response) with treatment. In certain aspects, the “treatment” administered before the relapse may be an RTK inhibitor.
[0196] A subject having a malignant tumor as disclosed herein, for example, non-small-cell carcinoma can be identified by routine medical examination, e.g., laboratory tests, organ functional tests, genetic tests, interventional procedure (biopsy, surgery) any and all relevant imaging modalities. In some aspects, a subject to be treated by the methods described hereinmay have one or more cancers or one or more tumors having at least one somatic mutation. In some aspects, a subject herein may have a cancer and / or tumor with one or more somatic mutations in an RTK gene (e.g., in a an EGFR gene, a HER2 gene, a HER3 gene, a HER4 gene, a c-Met gene, a ROS1 gene, a IGF-1R gene, a TRKA gene, a TRKB gene, a TRKC gene, a PDGFR gene, a VEGFR gene, a FGFR gene, a FLT3 gene, a NTRK gene, a RET gene, or any combination thereof. In some aspects, the subject to be treated by the methods described herein is a human cancer patient who has undergone or is subjecting to an anticancer therapy, for example, chemotherapy, radiotherapy, immunotherapy, or surgery. In some aspects, a subject shows disease progression through the treatment. In other aspects, a subject is resistant to the treatment (either de novo or acquired). In some aspects, such a subject is demonstrated as having advanced malignancies (e.g., inoperable or metastatic). Alternatively, or in addition, in some aspects, the subject has no standard therapeutic options available or ineligible for standard treatment options, which refer to therapies commonly used in clinical settings for treating the corresponding solid tumor.(b) Therapeutic Effects
[0197] In certain aspects, compositions and methods disclosed herein can treat and / or prevent cancer in a subject in need. In some aspects, compositions and methods disclosed herein can impair tumor growth compared to tumor growth in an untreated subject with identical disease condition and predicted outcome. In some aspects, tumor growth can be stopped following treatment with compositions disclosed herein. In other aspects, tumor growth can be impaired at least about 5% or greater to at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, or at least about 40% or greater to at least about 60% or greater compared to an untreated subject with identical disease condition and predicted outcome. In other words, tumors in subject treated using a composition of the disclosure have tumors that grow at least5% less (or more as described above) when compared to an untreated subject with identical disease condition and predicted outcome. In some aspects, tumor growth can be impaired at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, or at least about 100% compared to an untreated subject with identical disease condition and predicted outcome. In some aspects, tumor growth can be impaired at least about 5% or greater to at least about 10% or greater, at least about 10% orgreater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about 85% or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or greater, or at least about 95% or greater to at least about 100% compared to an untreated subject with identical disease condition and predicted outcome.
[0198] In some aspects, treatment of tumors with compositions and methods disclosed herein can result in a shrinking of a tumor in comparison to the starting size of the tumor. In some aspects, tumor shrinking is at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about 85% or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or greater, or at least about 95% or greater to at least about 100% (meaning that the tumor is completely gone after treatment) compared to the starting size of the tumor.
[0199] In certain aspects, compositions disclosed herein can improve patient life expectancy compared to the cancer life expectancy of an untreated subject with identical disease condition and predicted outcome. As used herein, “patient life expectancy” is defined as the time at which 50 percent of subjects are alive and 50 percent have passed away. In some aspects, patient life expectancy can be indefinite following treatment with a composition disclosed herein. In other aspects, patient life expectancy can be increased at least about 5% or greaterto at least about 100%, at least about 10% or greater to at least about 95% or greater, at least about 20% or greater to at least about 80% or greater, or at least about 40% or greater to at least about 60% or greater compared to an untreated subject with identical disease condition and predicted outcome. In some aspects, patient life expectancy can be increased at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, or at least about 100% compared to an untreated subject with identical disease condition and predicted outcome. In some aspects, patient life expectancy can be increased at least about 5% or greater to at least about 10% or greater, at least about 10% or greater to at least about 15% or greater, at least about 15% or greater to at least about 20% or greater, at least about 20% or greater to at least about 25% or greater, at least about 25% or greater to at least about 30% or greater, at least about 30% or greater to at least about 35% or greater, at least about 35% or greater to at least about 40% or greater, at least about 40% or greater to at least about 45% or greater, at least about 45% or greater to at least about 50% or greater, at least about 50% or greater to at least about 55% or greater, at least about 55% or greater to at least about 60% or greater, at least about 60% or greater to at least about 65% or greater, at least about 65% or greater to at least about 70% or greater, at least about 70% or greater to at least about 75% or greater, at least about 75% or greater to at least about 80% or greater, at least about 80% or greater to at least about 85% or greater, at least about 85% or greater to at least about 90% or greater, at least about 90% or greater to at least about 95% or greater, or at least about 95% or greater to at least about 100% compared to an untreated patient with identical disease condition and predicted outcome.
[0200] In some aspects, the methods of the present disclosure increase anti-tumor activity (e.g., reduce cell proliferation, tumor growth, tumor volume, and / or tumor burden or load or reduce the number of metastatic lesions over time) by at least about 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or more as compared to levels prior to treatment or in a control subject. In some aspects, reduction is measured by comparing cell proliferation, tumor growth, and / or tumor volume in a subject before and after administration of the pharmaceutical composition. In some aspects, the method of treating or ameliorating a cancer in a subject allows one or more symptoms of the cancer to improve by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or more. In some aspects, methods disclosed herein may include administration of the compositions herein to reduce tumorvolume, size, load or burden in a subject to an undetectable size, or to less than about 1 %, 2%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% of the subject's tumor volume, size, load or burden prior to treatment. In other aspects, methods disclosed herein may include administration of the compositions herein to reduce the cell proliferation rate or tumor growth rate in a subject to an undetectable rate, or to less than about 1 %, 2%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% of the rate prior to treatment.
[0201] In some aspects, a subject to be treated by any of the methods and / or compositions herein can present with one or more malignant tumors, metastatic nodes, or any combination thereof. In some aspects, a subject herein may have a cancerous tumor cell source that can be less than about 0.2 cm3to at least about 20 cm3or greater, at least about 2 cm3to at least about 18 cm3or greater, at least about 3 cm3to at least about 15 cm3or greater, at least about 4 cm3to at least about 12 cm3or greater, at least about 5 cm3to at least about 10 cm3or greater, or at least about 6 cm3to at least about 8 cm3or greater.
[0202] In certain aspects, the compositions disclosed herein can be effective for treating at least one tumor cell in a solid tumor from a subject in need. In some aspects, the amount of viable tumor cells may be reduced by at least about 5% or greater, at least about 10% or greater, at least about 15% or greater, at least about 20% or greater, at least about 25% or greater, at least about 30% or greater, at least about 35% or greater, at least about 40% or greater, at least about 45% or greater, at least about 50% or greater, at least about 55% or greater, at least about 60% or greater, at least about 65% or greater, at least about 70% or greater, at least about 75% or greater, at least about 80% or greater, at least about 85% or greater, at least about 90% or greater, at least about 95% or greater, or at least about 100% compared to an untreated subject with identical disease condition and predicted outcome.(c) Methods of administration
[0203] In some aspects, compositions of use herein can include at least one SUMOylation inhibitor as disclosed herein. In some other aspects, any combination therapy herein may include administering to a subject in need at least one RTK inhibitor and at least one SUMOylation inhibitor disclosed herein. In certain aspects, SUMOylation inhibitors disclosed herein can be administered to a subject alone or in combination with a RTK inhibitor, daily, every other day, twice weekly, every other day, every other week, weekly, monthly, or any other suitable dosing regimen.
[0204] Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the compositions disclosed herein to a subject, depending upon the type of disease to be treated or the site of the disease. In some aspects, compositions herein canbe administered to a subject by intravenous infusion, by subcutaneous administration, by inhalation, by intranasal administration or other mode of administration. In some aspects, compositions herein can be administered to a subject orally.
[0205] In some aspects, one or more disclosed active agents (e.g., SUMOylation inhibitor) can be administered concurrently with the one or more RTK inhibitor by the same or different modes of administration. In some aspects, one or more disclosed active agents (e.g., SUMOylation inhibitor) can be administered before, during or after the one or more SUMOylation inhibitors. In some aspects, the one or more SUMOylation inhibitors and / or the one or more SUMOylation inhibitors can be administered systemically. In certain aspects, the one or more RTK inhibitors and / or the one or more SUMOylation inhibitors can be administered locally directly to one or more tumors in the subject. In some aspects, the one or more RTK inhibitors and / or the one or more SUMOylation inhibitors can be administered by intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intra-arterial, intraarticular, intrasynovial, intrathecal, intratumoral, oral, inhalation or topical routes. In other aspects, the one or more RTK inhibitors and / or the one or more SUMOylation inhibitors can be administered to the subject by intravenous infusion.
[0206] An effective amount of the pharmaceutical composition described herein can be administered to a subject (e.g., a human) in need of the treatment via a suitable route, systemically or locally. In some aspects, one or more disclosed active agents can be administered by intravenous administration, e.g., as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intraarterial, intra-articular, intrasynovial, intrathecal, intratumoral, oral, inhalation, or topical routes. In some aspects, one or more disclosed active agents can be administered orally.
[0207] In some aspects, methods herein of treating a cancer with one or more SUMOylation inhibitors and / or RTK inhibitors as disclosed herein can further include treating a subject with at least one additional therapeutic regimen, for example, chemotherapy, radiotherapy, immunotherapy, or surgery. In some aspects, a subject treated with any of the methods herein can have completed an additional therapeutic regimen, be receiving an additional therapeutic regimen, or can receive an additional therapeutic regimen following treatment according to the methods herein.
[0208] In some aspects, any of the methods disclosed herein can further include monitoring occurrence of one or more adverse effects in the subject. Exemplary adverse effects include, but are not limited to, hepatic impairment, hematologic toxicity, neurologic toxicity, cutaneous toxicity, gastrointestinal toxicity, or any combination thereof. When one or more adverseeffects are observed, the method disclosed herein can further include reducing or increasing the dose of one or more of the disclosed active agents (e.g., SUMOylation inhibitor), the dose of one or more RTK inhibitor, or both depending on the adverse effect or effects in the subject. For example, when a moderate to severe hepatic impairment is observed in a subject after treatment, one or more compositions can be reduced in concentration, frequency of dosing, or any combination thereof.IV. Kits
[0209] The present disclosure provides kits for use in treating or alleviating cancer and / or a malignant tumor described herein. Such kits can include one or more containers including one or more disclosed agents (e.g., SUMOylation inhibitor). In some aspects, kits can include one or more containers including one or more one or more disclosed agents (e.g., SUMOylation inhibitor) and one or RTK inhibitors described herein.
[0210] In some aspects, the kits herein can include instructions for use in accordance with any of the methods described herein. The included instructions can have a description of administration of the one or more disclosed active agents (e.g., SUMOylation inhibitor), and / or the one or more RTK inhibitors described herein, to treat, delay the onset, or alleviate a target disease as those described herein, or any combination thereof. In some aspects, the kit can further include a description of selecting an individual suitable for treatment based on identifying whether that individual has the target disease, e.g., applying a diagnostic method as described herein. In still other aspects, the instructions can have a description of administering any one of the compositions described herein to an individual at risk of the target disease.
[0211] In some aspects, kit instructions relating to the use of one or more disclosed active agents (e.g., ALK inhibitor), one or more RTK inhibitors described herein, or any combination thereof can generally include information as to dosage, dosing schedule, and route of administration for the intended treatment. The containers can be unit doses, bulk packages (e.g., multi-dose packages) or sub-unit doses. Instructions supplied in the kits of the disclosure are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.
[0212] The label or package insert indicates that the composition is used for treating, delaying the onset and / or alleviating the solid tumor. In some aspects, instructions are provided for practicing any of the methods described herein.
[0213] The kits of this disclosure are in suitable packaging. Suitable packaging includes, but is not limited to, vials, bottles, jars, flexible packaging (e.g., sealed Mylar or plastic bags),and the like. Also contemplated are packages for use in combination with a specific device, such as an inhaler, nasal administration device (e.g., an atomizer) or an infusion device such as a minipump. In some aspects, a kit has a sterile access port (for example the container can be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). In some aspects, the container also has a sterile access port (for example the container is an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
[0214] In some aspects, kits herein can optionally provide additional components such as buffers and interpretive information. Normally, the kit comprises a container and a label or package insert(s) on or associated with the container. In some aspects, the disclosure provides articles of manufacture comprising contents of the kits described above.EXAMPLES
[0215] The following examples are included to demonstrate preferred aspects of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of the present disclosure, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific aspects which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the present disclosure.Example 1: Introduction to Examples
[0216] Molecularly targeted cancer therapy generally involves inhibition of specific oncogenic pathways, and has been most successful in the presence of activating mutations in receptor tyrosine kinase (RTK) pathways that result in accentuated signaling. However, secondary resistance to RTK inhibition remains a pervasive problem. In non-small cell lung cancer (NSCLC), activating EGFR mutations represent an important target. EGFR inhibition using tyrosine kinase inhibitors (TKIs) such as osimertinib is highly effective initially in the subset of patients with activating EGFR mutations. However, secondary resistance inevitably develops in initially responsive EGFR mutant tumors. The emergence of secondary resistance implies the survival of persister clones that are not eliminated during the initial treatment and is a major therapeutic hurdle.
[0217] In addition to NSCLC, a number of other cancers harbor activated receptor tyrosine kinases that serve as oncogenic drivers and respond to targeted therapies. For example, lapatinib is used in metastatic HER2+ breast cancer, and multiple RTK inhibitors such as sunitinib or caboxantinib have been used effectively in renal cell carcinoma (RCC). Multikinase RTK inhibitors are used for hepatocellular carcinoma (HCC) and include sorafenib which targets PDGFR and VEGFR. Gastrointestinal tumors expressing KIT are responsive to Imatinib, and lenvatinib and sorafenib are effective for thyroid cancers. While rapid signaling changes following RTK inhibition are well documented, the mechanisms that trigger these signaling events remain unknown.
[0218] The mechanisms of resistance to EGFR inhibition in NSCLC have been extensively investigated. Both mutational and non-mutational mechanisms of resistance have been described. For example, major mutational mechanisms of resistance to EGFR inhibition in NSCLC include secondary EGFR mutations such as the T790M mutation, and amplification of other RTKs such as MET. These genetic changes are detected after months of exposure to TKIs. In addition, inhibition of RTK signaling pathways in cancer cells leads to a rapid reprogramming of signaling pathways as the cancer cell seeks to restore homeostasis. This adaptive response to RTK inhibition may play a key role in early drug resistance and the formation of persister clones. It may also protect cells from a loss of RTK signals and could play an important role in mediating therapeutic resistance, although this has been difficult to prove in patients because of difficulty in obtaining tumor tissue at early time point after treatment. However, there is substantial evidence from experimental studies that EGFR inhibition triggers a rapid adaptive response in NSCLC that likely contributes to secondary resistance. A substantial component of this adaptive response includes activation of inflammatory signaling pathways. For example, upregulation of TNF and activation of NF-KB may play a central role in mediating survival of persister clones and secondary resistance to EGFR inhibition in NSCLC. For example, a rapid TNF-driven adaptive response may play a key role in resistance to EGFR inhibition in NSCLC and in glioblastoma (GBM). Bypass RTK signaling is also an important component of the RTK inhibition induced adaptive response. While rapid signaling changes following RTK inhibition are well documented, the mechanisms that trigger these signaling events remain unknown.
[0219] Protein modification by small ubiquitin-like modifier, termed SUMOylation plays an important role in multiple biological process in health and disease. SUMO regulated processes are found in multiple cancer hallmark functions. Enhanced SUMOylation can be oncogenic and correlate with poor prognosis. Expression of SUMO pathway enzymes is frequently upregulated in cancer including lung adenocarcinoma. SUMO enzymes are enriched in the nucleus but are also detected in the cytoplasm, and proteins in multiple cellular compartments including the plasma membrane can become SUMOylated. SUMOylation of proteins may have multiple molecular consequences and one outcome is that the attached SUMO acts as a platform to recruit new interacting proteins to the substrate.
[0220] Receptor tyrosine kinase inhibition is a commonly used treatment for variouscancers, leads to a loss of the tyrosine kinase activity of the RTK and is considered to render the receptor inactive. The following examples explore and define the surprising finding that kinase inhibited RTKs continue to function by becoming SUMOylated and converting to signaling platforms that drive adaptive resistance to RTK inhibition. In the examples, an EGFR mutant NSCLC was used as an exemplary model to examine this signaling function of kinase inhibited receptor tyrosine kinases and its role in therapeutic resistance.Example 2: Tyrosine kinase inhibition causes SUMOylation of EGFR
[0221] This example demonstrates that receptor tyrosine kinases are SUMOylated in response to tyrosine kinase inhibition (TKI).
[0222] A mass spectrometry experiment examining the association of proteins upon exposure of ligand or TKIs in EGFR mutant NSCLC cell lines was performed. It was noted that numerous proteins become associated with the mutant EGFR upon treatment with osimertinib (FIG. 1A). This was unexpected because proteins were expected to dissociate from the kinase-inhibited EGFR, not to become associated with it. Indeed, upon tyrosine kinase inhibition, numerous proteins were rapidly recruited to the EGFR in temporal waves. Osimertinib induced a rapid association of SUMO3 with the mutant EGFR suggesting that the EGFR may become SUMOylated, a post-translation modification that is implicated in key biological processes. SUMOylation of EGFR in response to osimertinib treatment by immunoprecipitating the EGFR followed by Western blot with SUMO3. EGFR became SUMOylated in response to the osimertinib in multiple oncogene-addicted EGFR mutant NSCLC cell lines (FIG. 1B-1D). SUMOylation of the EGFR was also detected in EGFR mutant HCC827 xenograft mouse tumors and in an EGFR mutant NSCLC patient derived xenograft (PDX) tumor treated with osimertinib (FIG. 1 E-1 F). siRNA knockdown of SUMO3 resulted in a loss of osimertinib-induced EGFR SUMOylation (FIG. 1G-1I), as did overexpression of SUMO specific protease 2 (SENP2) (FIG. 1J-1 K). Association of SUMO1 or SUMO2 to the EGFR upon treatment with osimertinib was not observed (FIG. 1L-1O). Nor was any change in EGFR stability detected with osimertinib in experiments using actinomycin D in EGFR mutant NSCLC cell lines (FIG. 1P). EGFR SUMOylation was also detected in response to erlotinib, a first-generation EGFR inhibitor (FIG. 1Q-1S).
[0223] Next, experiments were performed to determine whether RTK SUMOylation was specific to EGFR kinase inhibition or a general feature of tyrosine kinase inhibition of RTKs. RTK SUMOylation could be detected upon kinase inhibition of other RTKs as well. For example, kinase inhibition of ERBB2 with lapatinib, led to ERBB2 SUMOylation in the ERBB2- amplified cell lines BT474 and SK-BR-3 (FIG. 1T-1 U). Similarly, inhibition of MET with capmatinib in the Met-amplified lines H1993 and EBC1 resulted in MET SUMOylation (FIG.1V-1W), Also, inhibition of FGFR3 in RT112 and RT4 cell lines with infigratinib resulted in SUMOylation of FGFR3 (FIG. 1X-1Y). Additionally, inhibition of ALK with alectinib in ALK- mutant H2228 cells resulted in a robust SUMOylation of ALK (FIG. 1Z). PDGFRA SUMOylation in response to imatinib in H1703 cells could also be detected (FIG. 1AA).Example 3: EGFR SUMOylation is required for osimertinib-induced upregulation of TNF and activation of NF-KB
[0224] This example presents data showing that there are functional consequences of TKI- induced SUMOylation in various cell lines.
[0225] Previous studies have reported that TNF upregulation and NF-KB activation is a universal response to EGFR inhibition in EGFR mutant NSCLC. In fact, it was previously reported that TNF upregulation is a biologically significant and widespread outcome of EGFR inhibition in NSCLC and GBM. In these examples, EGFR mutant NSCLC and its response to osimertinib is used as a representative model to examine the mechanisms and biological significance of TKI induced RTK SUMOylation.
[0226] In a first set of experiments, it was found that siRNA knockdown of SUMO3 abolished osimertinib-induced TNF upregulation and NF-KB activation in multiple cell lines. Specifically, HCC827, PC9 and H3255 cells were transfected with siRNA SUMO3 or control siRNA for 48 h, followed by doses of osimertinib for 48 hr and then qPCR was performed to detect TNF mRNA. FIG. 2A-2C showed that SUMO3 siRNA suppressed TNF upregulation following Osimertinib treatment. Next, HCC827, PC9 and H3255 cells were transfected with SUMO3 or control siRNA for 48 hr, followed by doses of Osimertinib (50nM for PC9 and H3255, 100nM for HCC827) for 48 hr and then the concentration of TNF was measured in supernatants by ELISA. FIG. 2D-2F show that SUMO3 siRNA suppressed the increase in TNF protein levels observed after Osimertinib treatment. Finally, HCC827, PC9 and H3255 cells were transfected with SUMO3 or control siRNA for 48 hr, followed by indicated doses of osimertinib for 24 hr and then NF-KB activity was detected by a dual luciferase reporter assay. Renilla luciferase was used as an internal control. FIG. 2G-2I show that siSUMO3 treatment again suppressed the increase in NF-KB activity observed following Osimertinib treatment.
[0227] In a second set of experiments, neither TNF upregulation nor NF-KB activation were observed upon siRNA knockdown of EGFR. Specifically, HCC827 and PC9 cells were treated with Osimertinib or transfected with EGFR siRNA for 48 hr before a qPCR analysis or ELISA was performed to detect TNF mRNA regulation and expression levels respectively. Again, GAPDH was used as an endogenous control. FIGs. 2J and FIG. 2K show that siRNA knockdown of EGFR did not result in an upregulation of TNF that was observed with Osimertinib treatment, a result that was corroborated by TNF protein levels in cell supernatant(FIG. 2K and FIG. 2M). Finally, HCC827 and PC9 cells treated with Osimertinib or transfected with EGFR siRNA were tested for NF-KB activity using a dual-luciferase reporter assay using renilla luciferase as internal control. FIG. 2N and FIG. 20 show that EGFR knockdown (via treatment with EGFR siRNA for 48 hours) again does not result in the same increase in NF- KB activity observed following Osimertinib treatment over the same time frame. Collectively, these data suggested that this adaptive response to EGFR TKI inhibition required the presence of the kinase-inhibited EGFR.
[0228] In summary, the above data showed that siRNA knockdown of SLIMO3 abolished osimertinib-induced EGFR SUMOylation and blocks TNF upregulation and NF-KB activation in multiple cell lines. Importantly, TNF upregulation and NF-KB activation were not detected upon siRNA knockdown of the EGFR, suggesting that the adaptive response to EGFR TKI inhibition requires the presence of the kinase inhibited EGFR. These data indicated that the cellular response to EGFR TKIs is distinct from siRNA knockdown of the EGFR.Example 4: TRIM28 is the E3 ligase for EGFR SUMOylation in response to Osimertinib
[0229] A number of proteins have been reported to have E3 ligase activity in the SUMO pathway. As shown above in FIG. 1 A, it was found that TRIM28 becomes associated with the EGFR in response to osimertinib in EGFR mutant lung adenocarcinoma HCC827 cells. TRIM28 is known to have E3 SUMO ligase activity so a series of experiments were performed to evaluate its role in EGFR SUMOylation in response to osimertinib. First, it was confirmed that TRIM28 associated with the EGFR upon exposure to osimertinib by treating HCC827 and PC9 cells (both EGFR mutant NSCLC cell lines) with 100 nM and 50 nM Osimertinib, respectively, followed by immunoprecipitation with TRIM28 antibody and Western blot (FIG.3A-3B).
[0230] Next, HCC827 and PC9 cells were transfected with siRNA control and siRNA TRIM28, then treated with 100 nM and 50 nM osimertinib, respectively, followed by immunoprecipitation with EGFR antibody and Western blot. It was found that TRIM28 was knockdown inhibited that osimertinib-induced EGFR SUMOylation (FIG. 3C-3D). These data support an essential role for TRIM28 in osimertinib-induced EGFR SUMOylation. In another experiment, HCC827 and PC9 cells were transfected with siRNA control and siRNA UBC9, then treated by 100 nM and 50 nM osimertinib, respectively, followed by immunoprecipitation with EGFR antibody and Western blot. This experiment showed that siRNA knockdown of Ubc9, the known SUMO-conjugating enzyme also blocked osimertinib-induced EGFR SUMOylation (FIG. 3E-3F).Example 5: Identification of the site of osimertinib-induced EGFR SUMOylation
[0231] As noted, the previous examples establish that SUMO3, but not SUMO1 andSLIM02, becomes associated with the EGFR following treatment with osimertinib (FIG. 1A- 1F). This Example describes experiments performed to identify the site of Osimertinib-induced SUMOylation on the EGF Receptor.
[0232] K37 has been identified as a major site of SUMOylation of the wild type EGFR under basal conditions. Specifically, it was shown that EGFR was associated with SUMO-1 in the nucleus and with SUMO-2 / 3 in the cytoplasm. Therefore, using the most common EGFR mutations found in NSCLC (EGFR del 19 and L858R) as a template, the K37 residue was mutated. To examine the effects of the EGFR K37 mutant without the confounding effect of endogenous EGFR, this mutant receptor was introduced into H661 cells which do not express endogenous EGFR. CRISPR mediated gene editing was also used to knockout endogenous EGFR in H1975 cells (which normally express the L858R / T790M EGFR mutant). The H661 and H1975 EGFR knockout lines were then transfected to stably express EGFR del mutant, EGFR del 19 mutant with K37R mutation, EGFR L858R mutant, or EGFR L858R mutation with K37R mutation. Stable expression of EGFR in all transfected cell lines was confirmed with western blot (FIG. 4A-4B).
[0233] First, it was confirmed that mutants are functional by measuring EGF induced ERK activation via western blot (FIG. 4C-4F). It was found that K37R mutation in EGFR del 19 mutant or the L858R mutant resulted in a substantial inhibition of osimertinib-induced SUMOylation in H661 and H1975 cells (FIG. 4G-4J). Thus, K37 was a major site of EGFR SUMOylation in response to osimertinib. Experiments showed that osimertinib induced upregulation of TNF and activation of NF-KB are blocked in cells expressing EGFR del 19 and K37R or EGFRL858R and K37R double mutants (FIG. 4K-4R). To examine the effect of the K37R mutation on EGFR SUMOylation in oncogene addicted lines expressing endogenous mutant EGFR, HA-tagged EGFR del 19 mutant or del 19 plus K37R double mutant were transfected into HCC827 and PC9 cells and then treated the cells with osimertinib. This was followed by immunoprecipitation with HA antibodies and immunoblot with SUMO3 antibodies (FIG. 4S-4T). The results again demonstrated that the major site of osimertinib induced EGFR SUMOylation is K37 and that EGFR SUMOylation is required for osimertinib-induced TNF upregulation and NF-KB activation.
[0234] K37 is an extracellular residue and raises the question of how EGFR becomes SUMOylated on this residue. Importantly, previous studies support a cytoplasmic localization of NSCLC EGFR tyrosine kinase mutants including a constitutive endocytosis and cytoplasmic localization, and a rapid internalization of membrane-associated EGFR with EGFR TKIs. Localization of EGFR in HCC827 and PC9 cells was examined, and it was found that EGFR is found in multiple cellular compartments including plasma membrane and the cytoplasm, (FIG. 4U-4V). It was also demonstrated that EGFR associates with TRIM28 and Ubc9 inresponse to osimertinib in cytosolic extracts (FIG. 4X-4Y). This indicated that EGFR SUMOylation in response to osimertinib likely occurs in the cytosol.Example 6: EGFR inhibition leads to a SUMOylation dependent activation of NF-KB by recruiting a RIPK1 signaling complex
[0235] Receptor interacting protein kinase 1 (RIPK1) plays an essential role in NF-KB activation induced by various stimuli. NF-KB activation results in transcription of TNF and further NF-KB activation in a feedforward loop. Key steps in activation of NF-KB induces the formation of a RIPK1 complex with TRAF2. It was previously reported that RIPK1 becomes associated with the overexpressed EGFR and this results in NF-KB activation.
[0236] Experiments were conducted which show that RIPK1 forms a complex with EGFR upon treatment with osimertinib (FIG. 5A-5B). The osimertinib-induced association of RIPK1 with the EGFR requires EGFR SUMOylation because siRNA to SUMO3 inhibits binding of RIPK1 to the EGFR (FIG. 5C-5D). Importantly, in H1975 and H661 lines expressing the K37 deletion 19 mutant, RIPK1 was unable to bind EGFR in response to osimertinib, while RIPK1 binds EGFR deletion 19 mutant in H1975 and H661 cells (FIG. 5E-5F). Furthermore, siRNA to RIPK1 results in a loss of osimertinib-induced NF-KB activation (Fig. 5G-5H). As noted previously, osimertinib failed to activate NF-KB or upregulate TNF in H661 and H1975 lines expressing the K37 deletion 19 mutant.Example 7.- RTK inhibition of multiple RTKs results in a SUMOylation dependent NF-KB activation and TNF upregulation
[0237] Next, experiments were conducted to test if TNF upregulation and NF-KB activation was a general outcome of RTK inhibition with various tyrosine kinase inhibitors. It was found that RTK inhibition did result in an upregulation of TNF and NF-KB activation in most but not all the cell lines we tested. Thus, inhibition of ERBB2 in BT474 or SK-BR-3 cells resulted in TNF upregulation and NF-KB activation (FIG. 6A-6D), as did inhibition of Met in H1993 cells using capmatinib (FIG. 6E-6F). Similarly, inhibition of ALK using alectinib induced TNF upregulation and NF-KB activation in H2228 cells (FIG. 6G-6H), as did FGFR3 inhibition using infigratinib in R112 cells (FIG. 6I-6J). Importantly, in all these lines TKI induced TNF upregulation and NF-KB activation could be abrogated by using siRNA to SUMO3 consistent with the findings in NSCLC cell lines, and strongly supporting a requirement for RTK SUMOylation in generating these key adaptive signals (FIG. 6A-6J). However, TNF upregulation or NF-KB activation could not be detected in the H1703 cell line treated with imatinib to block the PDGFR (FIG. 6K-6L). An examination of the GEO database revealed that TNF upregulation activation is a common outcome of RTK inhibition in multiple cancer types (FIG. 6M-6R), supporting the view that TNF signaling could be a widespread contributorto therapeutic resistance to TKIs.Example 8: Bypass RTK signaling is SUMOylation dependent
[0238] RTK inhibition using TKIs leads to a well-documented bypass RTK signaling, in which there is activation or reactivation of another RTK not directly inhibited by the TKI, and that may play a role in adaptive resistance. Although there is considerable heterogeneity regarding which RTK is activated in response to a specific TKI treatment, bypass RTK signaling is a common outcome of RTK inhibition in multiple cancer types. To examine whether TKI-induced RTK SUMOylation is required for bypass RTK activation, the NSCLC cell line PC9 was examined and it was found that osimertinib induced an activation of ERBB3 in this line that was blocked by siRNA to SUMO3 (FIG. 7A). Furthermore, Met was activated in EGFR knockout H1975 cells expressing del 19 EGFR mutant in response to osimertinib. Importantly, osimertinib failed to activate Met in H1975 cells expressing the del19 K37R mutant indicating that EGFR SUMOylation was required for osimertinib induced activation of Met (FIG. 7B). Similarly, inhibition of Met in H1993 cells with capmatinib and bypass EGFR activation was blocked upon siRNA knockdown of SUMO3 (FIG. 7C). Also, treatment of BT474 or SK-BR-3 cells with lapatinib or RT112 cells with infigratinib resulted in activation of ERBB3 or Ret respectively that was blocked by siRNA knockdown of SUMO3 (FIG. 7D-7F). ALK inhibition using alectinib resulted in reactivation of ERBB2 that was blocked by siRNA knockdown of SUMO3 (FIG. 7G). Importantly, siRNA knockdown of EGFR failed to activate ERBB3 in PC9 cells (FIG. 7H). Similarly, siRNA knockdown of ERBB2 failed to activate ERBB3 in BT474 cells (FIG. 7I). Also, siRNA knockdown of Met failed to activate EGFR in H1993 cells (FIG. 7J). These data suggested that the kinase inhibited SUMOylated RTK is required to generate bypass RTK activation.
[0239] Next, the possibility that bypass RTKs may form complexes with the SUMOylated kinase inhibited RTK was considered. Indeed, it was found that osimertinib treatment of PC9 cells resulted in association of ERBB3 with the kinase inhibited EGFR that is blocked by siRNA knockdown of SUMO3 (FIG. 7K). Also, in H1975 cells expressing EGFR del 19 mutant, osimertinib induced an association of EGFR and Met, while this association could not be detected in H1975 cells expressing the del 19 / K37 mutant (FIG. 7L). Similarly, inhibition of ERBB2 with lapatinib induced an association with ERBB3 in BT474 cells that was blocked by siRNA to SUMO3 (FIG. 7M). Inhibition of Met with capmatinib resulted in an association of Met with EGFR in H1993 cells and this association is lost with siRNA knockdown of SUMO3 (FIG. 7N). These data further suggested that bypass RTK signaling requires the presence of the SUMOylated kinase inhibited receptor.Example 9: She and Grb2 association with bypass RTKs
[0240] Activation of RTKs results in association with secondary signaling proteins such as She or Grb2 that results in activation of downstream signaling networks. Experiments provided herein show that bypass RTK activation also involves the association of She and Grb2 with the activated bypass RTK. Furthermore, like the activation of the bypass RTK, the association of She and Grb2 with the activated bypass RTK is inhibited by siRNA knockdown of SLIMO3. Thus, She and Grb2 become associated with activated ERBB3 upon osimertinib treatment of PC9 cells and this association was blocked by siRNA to SLIMO3 (FIG. 8A-8B). Importantly, in H1975 expressing EGFR dell 9 mutant, osimertinib induced an association of She and Grb2 with the bypass activated Met, but not in H1975 del19 K37R mutant expressing cells (FIG. 8C-8D). Similarly, inhibition of ERBB2 with lapatinib in BT474 results in Grb2 and She association with ERBB3 that was blocked by siRNA knockdown of SLIMO3 (FIG. 8E-8F). Inhibition of Met with capmatinib resulted in Grb2 and She associated with the bypass activated EGFR, again blocked by siRNA knockdown of SLIMO3 (FIG. 8G-8H). These data supported a model in which bypass RTK signaling required SUMOylation of the kinase inhibited receptor.Example 10: EGFR SUMOylation in secondary resistant cell lines
[0241] Cell line models of secondary resistance to EGFR TKIs are useful tools to study mechanisms of resistance. EGFR mutant cell lines that have rendered experimentally resistant to EGFR TKIs were therefore examined. Two types of secondary resistant lines were used: HCC827 ER (erlotinib resistant) cell lines and H1975 OR (osimertinib resistant) cell lines. All the EGFR TKI resistant lines tested had a striking increase in EGFR SUMOylation (FIG. 9A-9B). It was previously reported that the erlotinib resistant lines have increased TNF levels. The osimertinib resistant lines similarly exhibit increased TNF and NF-KB activation compared to H1975 parental lines (FIG. 9C-9D). Importantly, siRNA knockdown of SUMO3 enhanced sensitivity to osimertinib in secondary resistant cell lines, strongly supporting the hypothesis that EGFR SUMOylation played an important role in resistance to osimertinib treatment (FIG. 9E-9F). These data supported a model in which EGFR SUMOylation plays a key role in resistance to EGFR TKIs.Example 11: EGFR SUMOylation induced resistance to osimertinib treatment in EGFR mutant NSCLC
[0242] Cell survival assays were conducted in HCC827 and PC9 cells. It was found that use of siRNA to SUMO3 sensitized these cells to osimertinib (FIG. 10A-10B). Importantly, expression of the SUMOylation defective K37 del 19 mutant EGFR in H661 and H1975 NSCLC cell lines that do not express endogenous EGFR resulted in enhanced sensitivity to osimertinib compared to expression of del19 mutant alone (FIG. 10C-10D) demonstrating that EGFRSUMOylation confers resistance to EGFR TKIs. Similar results were found with H661 or H1975 EGFR knockout cells expressing the EGFR L858R mutant of EGFR L858R plus K37 mutant (FIG. 10E-10F). Next, animal experiments were undertaken to examine whether EGFR SUMOylation influences the biological response to osimertinib in mouse models of EGFR mutant NSCLC. Tumors generated from H1975 EGFR knockout cells stably expressing the EGFR del19 / K37R double mutant were more responsive to osimertinib treatment compared to H1975 EGFR knockout tumors expressing the single del 19 mutant (FIG. 10G). A similar result was found in H661 cells expressing the double mutant (EGFR del19 / K37R) compared to the single del 19 mutant (FIG. 10H). Next, it was examined if SUMO activating enzyme (SAE) inhibitor TAK-981 currently in clinical trials, would synergize with osimertinib in mouse models. Indeed, TAK-981 synergized with osimertinib in a PC9 derived mouse model, as well as in an EGFR mutant PDX model (HCC4190) (FIG. 10I-10J). These data indicated that EGFR TKI induced EGFR SUMOylation is biologically significant and could play a role in therapeutic resistance. Furthermore, a combination of TKI plus SUMO inhibition could be a useful treatment approach.Example 12: EGFR SUMOylation in TKI treated NSCLC patient tissues
[0243] Next, proximity ligation assays (PLA) were used to detect SUMOylation of EGFR in cultured cells and found EGFR and SUMO-3 interaction in response to osimertinib (FIG 11A). EGFR-SUMO3 interaction in HCC827 mouse tumors treated with Osimertinib was detected (FIG 11B Fig. 9B). More importantly, EGFR SUMOylation in resected tissue from post TKI treated patient paraffin embedded tissue, and a substantial localization of SUMOylated EGFR in the cytoplasm could also be detected. TKI-naTve and TKI-treated tissues (n=29) were examined next. EGFR SUMOylation was consistently found in TKI treated tumor tissue but not in TKI naive tissue as shown in representative sections from 3 TKI naive and 3 TKI treated patients (FIG 11C-11D and FIG. 11G). Evidence of post-TKI treatment EGFR SUMOylation was also found in two sets of paired pre- and post-TKI tissues from the same patients (FIG 11 E-11 F).Example 13: Discussion of Examples
[0244] Targeted therapy using tyrosine kinase inhibitors represents a major advance in the treatment of multiple cancers. By inhibiting kinase activity, TKIs shut down receptor signal transduction. The major finding of the examples disclosed herein is that, in contrast to prior assumptions, receptor tyrosine kinases do not become inert upon TKI treatment. Instead, they undergo a rapid SUMOylation, which in turn, leads to an alternate signal transduction in which the kinase-inhibited RTK now functions as a hub to continue to signal as an adaptor platform. The term “escape RTK signaling” is used herein to describe this continued signal transductionby kinase-inhibited receptors. Escape RTK signaling is distinct from the well documented concept of bypass RTK signaling in which a different RTK becomes activated when a given RTK is inhibited by its specific TKI. An important outcome of protein SUMOylation is that SUMO acts as a platform that recruits new interacting proteins to the SUMOylated protein. The findings described in the examples indicated that SUMOylation of the kinase inhibited RTK triggers activation of specific adaptive signals that promoted resistance. The SUMOylation of RTKs in response to TKI inhibition was detected with multiple receptors and TKIs in multiple cancer cell lines with aberrant RTK signaling. Examples include, EGFR / osimertinib, MET / capmanitnib, ERBB2 / lapatinib, FGFR3 / infigratinib and ALK / alectinib. These data suggest that RTK SUMOylation may be a general outcome of RTK inhibition by TKIs. However, since TKIs are clearly effective in multiple oncogene-addicted cancers acting by suppression of RTK kinase activity, the escape RTK signaling transduced by the kinase inactive SUMOylated RTK cannot be identical to signaling generated by the non-inhibited receptor, and may play a role in secondary resistance which emerges later. Additionally, continued signal transduction by kinase inhibited SUMOylated RTKs could be an important factor underlying the limited effectiveness of TKIs in general, and could also play a role in intrinsic or primary resistance.
[0245] Signal transduction by the kinase-inhibited EGFR in EGFR mutant NSCLC as a representative disease model were further studied. Surprisingly, osimertinib treatment of lung cancer cells induced a recruitment of multiple proteins to the kinase inhibited EGFR. SUMO3 is among these proteins and it was found that the mutant EGFR becomes rapidly SUMOylated in response to osimertinib. A major site of osimertinib-induced EGFR SUMOylation was identified as K37 and it was found that mutation of this EGFR SUMOylation site or siRNA knockdown of SUMO3 resulted in a loss of key adaptive signals triggered by osimertinib such as TNF-NF-KB and bypass RTK signaling and enhanced the sensitivity of EGFR mutant tumors to osimertinib in mouse models. Use of a SUMO inhibitor also enhances the sensitivity of EGFR mutant tumors to osimertinib. A study of cell lines rendered secondarily resistant to EGFR TKIs showed a large increase in EGFR SUMOylation in every line tested and a reversal of TKI resistance upon siRNA knockdown of SUMO3. Importantly, using a proximity ligation assay (PLA), the association of EGFR and SUMO3 in post-TKI treated mouse tumors and human NSCLC tissue was demonstrated. SUMOylation has no effect on EGFR stability. Notably, SUMO inhibitors sensitize NSCLC tumors to osimertinib in mouse models.
[0246] Without wishing to be bound by theory, inhibition of RTKs is understood to lead to a rapid activation of multiple intracellular signaling pathways, such as TNF-NF-KB, ERK, or STAT3 activation, which may promote the survival of persister clones. What triggers these early compensatory signals is a fundamentally important and unanswered question. The datapresented here indicated that the kinase-inactive EGFR itself served as the nidus to trigger the adaptive response. Thus, TNF upregulation and NF-KB activation were readily detected following treatment with EGFR TKIs but, importantly, not upon siRNA knockdown of the EGFR. These findings suggested that the cellular response to EGFR kinase inhibition was distinct from loss of EGFR expression. It should be noted that siRNA knockdown of signaling proteins also led to compensatory signaling changes, for example siRNA knockdown of Akt leads to upregulation of RTKs.
[0247] TNF upregulation and NF-KB activation is a key component of adaptive resistance in NSCLC. Data presented in the examples herein showed that it is a widespread response to RTK inhibition with TKIs that is SUMOylation dependent. The data presented herein in the examples also showed that TKI-induced SUMOylation of the EGFR recruits RIPK1 , a key component of the NF-KB activation network to the kinase inhibited EGFR leading to NF-KB activation. NF-KB activation leads to increased induction of TNF, which in turn, leads to further NF-KB activation in a feed forward loop.
[0248] RTK bypass signaling or kinome rewiring is detected upon RTK inhibition in multiple cancers and is likely to play a key role in adaptive resistance. Remarkably, RTK SUMOylation involved in bypass of RTK signaling. While there is considerable heterogeneity in the specific bypass RTK that is activated upon inhibition of a particular RTK in cancer cell lines, bypass RTK signaling appeared to be dependent on TKI-induced SUMOylation. Thus, without wishing to be bound by theory, it is believed that RTK SUMOylation leads to recruitment of bypass RTKs and associated secondary signaling proteins such as She and Grb2 to the kinase inhibited receptor leading to bypass RTK inhibition. Bypass RTK may heterodimerize with the kinase inhibited RTK or, the SUMOylated kinase inhibited RTK may provide a platform for the self-dimerization or oligomerization of the bypass RTK.
[0249] TKIs have been widely used for cancer treatment for decades, but their effectiveness is limited due to therapeutic resistance. The examples provided herein indicate that tyrosine kinase inhibition does not abrogate signaling by the kinase-inhibited RTK. While the kinase activity was suppressed by TKIs, the kinase inhibited RTK becomes SUMOylated and continued to signal. Thus, the SUMOylated RTK escaped the constraints of kinase inhibition by transforming into an adaptor signaling platform. Without wishing to be bound by theory, post-TKI SUMOylation of RTKs may serve a central mechanism underlying the rapid compensatory signaling changes that have been extensively documented following TKI exposure. The finding that tyrosine kinase inhibition does not shut down RTK signaling, and instead continues to signal as an adaptor that generating survival signals, would seem to suggest that alternative methods to inhibiting receptors or combining SUMOylation inhibitors with RTK inhibitors maybe more effective. Thus, the identification of key mechanisms drivingresistance to TKIs, such as RTK SUMOylation may open avenues to enhance the effectiveness of targeted treatment using TKIs.Example 13: Materials and Methods used in the Examples
[0250] Cell lines and drugs. RT4 and EBC-1 were purchased from Millipore-Sigma. RT 112 was purchased from CLS Cell Lines Service GmbH. BT474 was purchased from the American Type Culture Collection. HCC827 / ER3, HCC827 / ER4(A) and HCC827 / ER4(B) have been described previously. H1975 / OR5 and H1975 OR16 were provided by Dr. John V. Heymach (MD Anderson Cancer Center, Houston), and the method of generating these lines has been described previously65. SK-BR-3 and all other NSCLC cell lines including HCC827, PC9, H3255, H661 , H1975, H1993, H2228 and H 1703 were from the Hamon Center for Therapeutic Oncology Research at UT Southwestern Medical Center. RT112 was cultured in RPMI-1640 containing 10% FBS. SK-BR-3 and RT4 were cultured in McCoy’s 5A containing 10% FBS. All other cell lines were cultured in RPMI-1640 containing 5% FBS. Cell lines were authenticated by DNA fingerprints for cell-line individualization using Promega Stem Elite ID system, a short tandem repeat (STR)-based assay, at UT Southwestern Medical Center Genomics Core. Cells were tested for Mycoplasma contamination using an e-Myco kit (Boca Scientific).
[0251] Osimertinib (#16237), lapatinib (#11493), imatinib (mesylate) (#13139), capmatinib (#20056), infigratinib (#19157), TAK-981 (#32741), and alectinib (#18516) were obtained from Cayman Chemical.
[0252] siRNA. Human EGFR (L-003114-00-0005), TRIM28 (L-005046-00-0005), SUMO3 (L-019730-00_,0005), ERBB2 (L-003126-00-0005) and MET (L-003156-00-0005) siRNA were obtained from Dharmacon. siRNA pool from Dharmacon contain four sequences for each target. Human UBC9 (sc-36773) and scrambled siRNA (sc-37007) were purchased from Santa Cruz Biotechnology. siRNA pool from Santa Cruz Biotechnology contains three sequences for each target. Cells were transfected with the siRNA pool using lipofectamine RNAiMAX (Invitrogen). Experiments were conducted 48 hr after siRNA transfection.
[0253] Construction of lentiviral vectors and cell lines. DNA fragments encoding proteins of interest were amplified by PCR with Q5 Hot Start High-Fidelity 2 x Master Mix. The amplified DNA fragments were purified and cloned into pLX317 vector (Nhel / Mlul sites) using NEBuilder HiFi DNA Assembly Master Mix. Inserted sequences were further validated by Sanger sequencing. EGFRK37Rwas generated by replacing K37 with R using PCR.
[0254] To package lentivirus, HEK293T cells were seeded in a 6-well plate at a confluency of ~ 90% were transfected with 1.2 ug pLX137 plasmid carrying the gene of interest, together with 0.5 ug envelope plasmid pMD2.G and 0.8 ug packaging plasmid psPAX2 using effectenetransfection reagent according to manufacturer’s manual. Culture medium were collected 48 hr post transfection and filtered through 0.45 mm sterilized Millex-HV Syringe Filters (Millipore) as lentivirus preparation. Lentivirus infection was carried out by adding lentivirus into cell culture medium supplemented with 2 mg / mL protamine sulfate. 48 hr post infection, lentivirus was removed by changing with fresh culture medium. In all experiments, lentivirus amount was titrated to achieve expression level comparable to that of endogenous proteins, as confirmed by western blotting or quantitative real-time PCR.
[0255] CRISPR-Cas9 genomic editing for gene deletion was performed as previously described. For deletion of the gene encoding EGFR, two TrueGuide Mod EGFR-sgRNA (ThermoFisher, A35533) and TrueCut Cas9 Proteins (ThermoFisher, A36498) were transfected by Neo Tranfection Kit (ThermoFisher, MPK10025K).
[0256] Western blot and antibodies. Western blot was performed according to standard protocols. Western blot results were representative of at least three independent experiments. EGFR (#06- 847) antibody was from EMD Millipore; p-EGFR(Tyr1068) (#2236), p-ERBB3 (#4791), ERBB3 (#12708), p-ERBB2 (Tyr1221 / 1222) (#2243), ERBB2 (#4290), HA-Tag (#2367), Phospho-p44 / 42 MAPK (Erk1 / 2) (#4370), p44 / 42 MAPK (Erk1 / 2) (#4696), TIFip (KAP1 / TRIM28) (#4123), UBC9 (#4786) , p-MET (Tyr1234 / 1235) (#3077), MET (#8198), p- PDGF Receptor a (Tyr754) (#2992), PDGF Receptor a (#5241), Lamin A / C (#4777), E-Cadherin (#3195), p-ALK (Tyr1604) (#3341), ALK (#3633), p-RET (Tyr905) (#3221), RET (#14556) and GRB2 (#3972) antibodies were from Cell Signaling Technology; p-actin (sc-47778), SUMO-3 (sc-130884), SUMO-1 (sc-5308), FGFR-3 (sc-390423), GAPDH (sc-47724) and SHC (sc-967) antibodies were from Santa Cruz Biotechnology. RIPK1 (#610459) antibody was from BD biosciences. SUMO-2 (VMA00340) antibody was from Bio-Rad. p-FGFR3 (Tyr724) (AP1274) antibody was from ABclonal Technology.
[0257] Immunoprecipitation and Immunoblot Analysis of SUMOylation. Cells were lysed with 100 ul of denaturing lysis solution (0.15 M Tris-HCI, pH 6.7, 5% SDS, and 30% glycerol), which was then diluted 1 :10 in PBS / 0.5% NP40 plus complete protease inhibitor (Roche). If the lysate was highly viscous, sonication was performed until viscosity was reduced. Lysates were centrifuged at 16,000g for 10 min at 4 °C to remove cellular debris. Immunoprecipitation was performed with anti-EGFR beads (CST, #5735), HA-Tag beads (3956), MET beads (SantCruz, sc-8057 AC), FGFR-3 beads (SantCruz, sc-390423 AC), ERBB2 beads (SantCruz, sc-33684 AC), PDGF Receptor a beads (SantCruz, sc-398206 AC) and ALK beads (SantCruz, sc-398791 AC) for overnight at 4 °C. Thereafter, the precipitants were washed four times with washing buffer (PBS / 0.5% NP40 plus complete protease inhibitor), and the immune complexes were 2 x SDS sample buffer and separated on an SDS- PAGE, followed by Immunoblot analysis.
[0258] For co-IP, cell lysis buffer (CST, #9803) was used in place of of the lysis buffer above. Immunoprecipitation was performed with above beads, SHC beads (SantCruz, sc- 967 AC) and GRB2 beads (SantCruz, sc-8034 AC).
[0259] Real-time PCR and primers. cDNA synthesis and real-time PCR Total RNA was isolated by TRIzol Reagent (Fisher Scientific). cDNA reverse transcription was performed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Each PCR reaction was carried out in triplicate in a 20-pl volume using SYBR Green Master Mix (Applied Biosystems). Values for each gene were normalized to expression levels of GAPDH mRNA GAPDH. Primer sequences were as follows. GAPDH, 5’-GTGAAGGTCGGAGTCAACGG-3’ (forward) (SEQ ID NO:1), 5’-TGATGACAAGCTTCCCGTTCTC-3’ (reverse) (SEQ ID NO:2); TNF, 5’-CCCAGGGACCTCTCTCTAATCA-3’ (forward) (SEQ ID NO:3), 5’-GCTACAGGCTTGTCACTCGG-3’ (reverse) (SEQ ID NO:4). These primers were synthesized by Millipore-Sigma.
[0260] Cell viability assay. Cell viability assays were conducted with alamarBlue cell viability reagent from Thermo Fisher Scientific, following the manufacturer’s protocol. Cells were cultured in Corning 96-well black plates with clear bottom and detected by the POLARstar Omega Microplate Reader (BMG LABTECH) (excitation at 544 nm and emission at 590 nm). At least three independent experiments were performed.
[0261] Luciferase assays. Cells were transfected with NF-KB and Renilla luciferase plasmid by Lipofectamine 2000. Renilla luciferase was co-transfected as an internal control. A dual-luciferase reporter assay system (Promega) was used according to the manufacturer’s protocol. Firefly luciferase activity was measured in the POLARstar Omega Microplate Reader (BMG LABTECH) and normalized based on Renilla luciferase activity. NF-KB luciferase plasmid was provided by Ezra Burstein (UT Southwestern).
[0262] ELISA. To detect TNF levels in medium, cells were cultured in serum-free medium and treated with indicated drugs for 48 h. Supernatant was then collected and concentrated using a Pierce protein concentrator (Thermo Fisher Scientific). Then, the levels of TNF protein were measured by ELISA using human TNF ELISA kit (BD Bioscience, 550610) according to the manufacturer’s protocol.
[0263] DuoLink in Situ Proximity Ligase Assay (PLA). Two primary antibodies (SUMO3, santa cruz sc-130884 and EGFR, invitrogen PA1-1110) raised in different species are used to detect two unique protein targets. A pair of oligonucleotide-labeled secondary antibodies (PLA probes) then binds to the primary antibodies. Next, hybridizing connector oligos join the PLA probes only if they are in close proximity to each other and ligase forms a closed, circle DNA template that is required for rolling-circle amplification (RCA). The PLA probe then acts as aprimer for a DNA polymerase, which generates concatemeric sequences during RCA. This allows up to 1000-fold amplified signal that is still tethered to the PLA probe, allowing localization of the signal. Lastly, labeled oligos hybridize to the complementary sequences within the amplicon, which are then visualized and quantified as discrete spots (PLA signals). Analysis was conducted with a Laser scanning confocal Zeiss LSM780 microscope, at 40* magnification.
[0264] Animal study. Cell lines. Athymic mice (088) at 4-6 weeks old were purchased from Charles River Laboratories. Mice were injected with 100 pl Matrigel containing 5 * 106H661 (stable cell lines derived) and PC9 cells in the right flank. Two million (2 x 106) H1975 (stable cell lines derived) were injected subcutaneously into the flanks of Athymic mice. About 2 weeks later, mice developed subcutaneous tumors. Mice were randomly divided into the indicated groups. Mice were treated with drugs using doses described in figure legends. For combination treatment, both drugs were given concurrently for the indicated period. Tumor dimensions were measured every 4 d and tumor volumes were calculated by the formula: volume = 0.5 x length x width x width. Mice were euthanized when tumors reached >2000 mm3in length or after the indicated number of days.
[0265] PDX NSCLC specimens (P0) for HCC4190 PDXs were surgically resected from a patient diagnosed with NSCLC at UT Southwestern Medical Center, after obtaining Institutional Review Board (IRB) approval and informed consent. HCC4190 harbors EGFR L858R mutation identified by exome sequencing. The 4-6-week-old female NOD-SCID mice (001303) were purchased from Jackson Laboratory. PDX tumor tissues were cut into small pieces (~20 mm3) and subcutaneously implanted into NOD-SCID mice of serial generations (P1 , P2 and so on). P4 tumor-bearing SCID mice were used in this study.
[0266] Patient data. Patient formalin-fixed, paraffin-embedded (FFPE) tissues were obtained from UT Southwestern Medical Center (n = 29), including two paired patients slides. Twenty slides were from patients treated with TKI prior to the tissue collection (15 slides are from erlotinib treated patients and 5 slides are from osimertinib treated patients), while nine were never treated with TKI before.
[0267] For Gene Set Enrichment Analysis (GSEA) of the transcriptome, twelve-TNF / NF-KB related signaling were downloaded from Reactome Pathway Database to establish a local TNF / NF-KB related gene set. Then, we used the TNF / NF-KB related gene set with weighted enrichment statistic and signal-to-noise metric for expression matrix, and 1 ,000 permutations.
[0268] Study approval. All animal studies were performed under Institutional Animal Care and Use Committee-approved protocols at UT Southwestern Medical Patient tissues and medical records were obtained from UT Southwestern Medical Center with IRB approval.
[0269] Statistics. Error bars represent the mean ± s.e.m. of three independent experiments unless indicated otherwise. Combination effects in vivo were analyzed by two-way ANOVA with Bonferroni’s correction to adjust significance level for multiple comparisons. ELISA experiments were analyzed by two-tailed one-sample Student’s t-test, two-tailed two-sample Student’s t-test. The family-wise error rate was set at 0.05. All analyses above were performed using GraphPad Prism 9 software. P value, or an adjusted P value for multiple comparisons, <0.05 was considered statistically significant (*p < 0.05, **p < 0.01 , ***p < 0.001 , p > 0.05, not statistically significant). Data from cell survival assay, qPCR assay and luciferase assay were presented as mean lines with three dots from three cell cultures within one.
Claims
CLAIMSWhat is claimed is:
1. A method of treating a cancer in a subject, comprising administering to the subject in need thereof: a. at least one receptor tyrosine kinase (RTK) inhibitor; and b. at least one SUMOylation inhibitor, wherein the subject has or is suspected of having a malignant tumor.
2. The method of claim 1 , wherein the RTK inhibitor comprises an epidermal growth factor receptor (EGFR) inhibitor, a HER2 inhibitor, a HER3 inhibitor, a HER4 inhibitor, a pan- HER inhibitor, a platelet-derived growth factor (PDGF) / Kit receptor inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor, a fibroblast growth factor (FGF) receptor inhibitor, a hepatocyte growth factor (HGF receptor) inhibitor, a mesenchymal-epithelial transition factor receptor (MET) inhibitor, an insulin or insulinlike growth factor (IGF) receptor inhibitor, or any combination thereof.
3. The method of any one of claims 1 or 2, wherein the at least one RTK inhibitor comprises a peptide, an antibody, a small molecule, an oligo, a nucleic acid molecule, or any combination thereof.
4. The method of claim 3, wherein the at least one RTK inhibitor comprises a small molecule comprising osimertinib, imatinib, capmatinib, linsitinib, infigratinib, avapritinib, pemigatinib, ripretinib, selpercatinib, tucatinib, entrectinib, erdafitinib, pexidartinib, dacomitinib, gilteritinib, acalabrutinib, midostaurin, neratinib, cobimetinib, lenvatinib, nintedanib, afatinib, trametinib, axitinib, cabozantinib, ponatinib, regorafenib, tofacitinib, vandetanib, pazopanib, lapatinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, gefitinib, imatinib, varlinitib, infigratinib, mobocertinib, pralsetinib, tepotinib, tivozanib, trastuzumab, aflibercept, larotrectinib, trastuzumab, pertuzumab, amivantamab, bevacizumab, margetuximab, necitumumab, ramucirumab, panitumumab, cetuximab, derivatives thereof, or any combination thereof.
5. The method of claim 1 , wherein the at least one SUMOylation inhibitor comprises a small peptide, a protein, an antibody, a small molecule, an oligo, a nucleic acid molecule, or any combination thereof.
6. The method of claim 5, wherein the at least one SUMOylation inhibitor comprises a small molecule comprising anacardic acid, 2-hydroxy-5-nitrobenzylidene thiazolidine-4-one (2-HNB), ginkgolic acid, N-ethylmaleimide (NEM), SNEP inhibitors, kerriamycin B, compound 21 , davidiin, tannic acid, ML-792, COH-OOO, TAK-981 , ML-93, GSK145A, 2-D08, spectomycin B, GN6958, SUMO-based Ubc9 inhibitors (SLIBINs), triptolide, GN6958, momordin Ic (Me), nocardione A, dunnione, dehydrodunnione, - lapachone, streptonigrin, ebselen, vialinin A and derivatives thereof, or any combination thereof.
7. The method of claim 1 , wherein the method comprises administering a. and b. concurrently, or administering a. and b. separately.
8. The method of claim 1 , wherein the malignant tumor comprises a carcinoma, a sarcoma, a hematological malignancy or any combination thereof.
9. The method of claim 8, wherein the malignant tumor comprises a lung tumor, a breast tumor, a pancreatic tumor, a colorectal tumor, an esophageal tumor, a head-and-neck tumor, a hematological malignancy, a brain tumor, an ovarian tumor, a stomach tumor, a gastric tumor, a gastrointestinal stromal tumor, a prostate tumor, a thyroid tumor, bladder tumor, dermatofibrosarcoma protuberans, a giant cell tumor, a lymphoma, melanoma, a myeloma, a kidney tumor, a soft tissue sarcoma, chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), urothelial carcinoma, a cervical tumor, liver or bile duct tumor, endometrial tumor or any combination thereof.
10. The method of any one of claims 8 or 9, wherein the malignant tumor is derived from a non-small-cell lung cancer (NSCLC), HER-2 positive breast cancer, glioblastoma, gastrointestinal stromal tumor, esophageal tumor, liver or bile duct tumor, bladder tumor or any combination thereof.
11. The method of any one of claims 1 , or 8-10, wherein the malignant tumor has one or more somatic mutations, translocations, amplifications, and / or other disruptions in at least one gene encoding an RTK.
12. The method of claim 11 , wherein the at least one gene encoding a RTK comprises an EGFR gene, a HER2 gene, a HER3 gene, a HER4 gene, a c-Met gene, a ROS1 gene, a IGF-1 R gene, a TRKA gene, a TRKB gene, a TRKC gene, a PDGFR gene, a VEGFR gene, a FGFR gene, a FLT3 gene, a NTRK gene, a RET gene or any combination thereof.
13. A pharmaceutical composition comprising at least one receptor tyrosine kinase (RTK) inhibitor, at least one SUMOylation inhibitor, and an excipient.
14. The pharmaceutical composition of claim 13, wherein the RTK inhibitor comprises an epidermal growth factor receptor (EGFR) inhibitor, a HER2 inhibitor, a HER3 inhibitor, a HER4 inhibitor, a pan-HER inhibitor, a platelet-derived growth factor (PDGF) / Kit receptor inhibitor, a vascular endothelial growth factor receptor (VEGFR) inhibitor, a fibroblast growth factor (FGF) receptor inhibitor, a hepatocyte growth factor (HGF receptor) inhibitor, a mesenchymal-epithelial transition factor receptor (MET) inhibitor, an insulin or insulin-like growth factor (IGF) receptor inhibitor, or any combination thereof.
15. The pharmaceutical composition of claims 13 or 14, wherein the at least one RTK inhibitor comprises a peptide, an antibody, small molecule pharmaceutical compound, an oligo, a nucleic acid molecule, or any combination thereof.
16. The pharmaceutical composition of claim 15, wherein the at least one RTK inhibitor comprises a small molecule comprising osimertinib, imatinib, capmatinib, linsitinib, infigratinib, avapritinib, pemigatinib, ripretinib, selpercatinib, tucatinib, entrectinib, erdafitinib, pexidartinib, dacomitinib, gilteritinib, acalabrutinib, midostaurin, neratinib, cobimetinib, lenvatinib, nintedanib, afatinib, trametinib, axitinib, cabozantinib, ponatinib, regorafenib, tofacitinib, vandetanib, pazopanib, lapatinib, nilotinib, dasatinib, sunitinib, sorafenib, erlotinib, gefitinib, imatinib, varlinitib, infigratinib, mobocertinib, pralsetinib, tepotinib, tivozanib, trastuzumab, aflibercept, larotrectinib, trastuzumab, pertuzumab, amivantamab, bevacizumab, margetuximab, necitumumab, ramucirumab, panitumumab, cetuximab, derivatives thereof, or any combination thereof.
17. The pharmaceutical composition of claim 13, wherein the at least one SUMOylation inhibitor comprises a small peptide, a protein, an antibody, a small molecule pharmaceutical compound, an oligo, a nucleic acid molecule, or any combination thereof.
18. The pharmaceutical composition of claim 17, wherein the at least one SUMOylation inhibitor comprises a small molecule comprising anacardic acid, 2-hydroxy-5- nitrobenzylidene thiazolidine-4-one (2-HNB), ginkgolic acid, N-ethylmaleimide (NEM), SNEP inhibitors, kerriamycin B, compound 21 , davidiin, tannic acid, ML-792, COH- 000, TAK-981 , ML-93, GSK145A, 2-D08, spectomycin B, GN6958, SUBINs, triptolide, GN6958, momordin Ic (Me), nocardione A, dunnione, dehydrodunnione, p-lapachone, streptonigrin, ebselen, vialinin A and derivatives thereof, or any combination thereof.
19. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is for administration into a subject in need thereof, wherein the subject has or is suspected of having a malignant tumor.
20. The pharmaceutical composition of claim 19, wherein the malignant tumor comprises a carcinoma, a sarcoma, a hematological malignancy, or any combination thereof.
21. The pharmaceutical composition of claim 20, wherein the malignant tumor comprises a lung tumor, a breast tumor, a pancreatic tumor, a colorectal tumor, an esophageal tumor, a head-and-neck tumor, a hematological malignancy, a brain tumor, an ovarian tumor, a stomach tumor, a gastric tumor, a gastrointestinal stromal tumor, a prostate tumor, a thyroid tumor, bladder tumor, dermatofibrosarcoma protuberans, a giant cell tumor, a lymphoma, melanoma, a myeloma, a kidney tumor, a soft tissue sarcoma, chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), urothelial carcinoma, a cervical tumor, liver or bile duct tumor, endometrial tumor ,or any combination thereof.
22. The pharmaceutical composition of any one of claims 13-21 , formulated for parenteral, oral, or transmucosal delivery.
23. A method of treating a tumor in a subject in need thereof comprising administering to the subject at least one SUMOylation inhibitor, wherein the subject has undergone, is undergoing, or will undergo an anti-cancer therapy comprising one or more targeted receptor tyrosine kinase (RTK) inhibitors.
24. The method of claim 23, wherein the tumor is resistant to or may develop resistance to the anti-cancer therapy comprising one or more targeted RTK inhibitors.
25. The method of claim 23, wherein the targeted RTK inhibitor is an EGFR / ERBB inhibitor.
26. The method of any one of claims 23, wherein the subject responds to the RTK inhibitor over a longer time period than a subject that did not receive the SUMOYIation inhibitor.
27. A method of preventing sensitization and / or resistance to an anti-cancer therapy comprising a receptor tyrosine kinase (RTK) inhibitor, the method comprising administering to a subject in need thereof, an SUMOylation inhibitor prior to or concurrent with the anti-cancer therapy comprising the RTK inhibitor.
28. A method of increasing sensitivity of a cancer cell to a receptor tyrosine kinase (RTK) inhibitor comprising: contacting a cancer cell with at least one SUMOylation inhibitor, where the cancer cell is sensitized and / or resistant to a receptor tyrosine kinase (RTK) inhibitor, wherein the at least one SUMOylation inhibitor increases the cell’s sensitivity to an RTK inhibitor as compared to a cell not contacted with SUMOylation inhibitor.
29. The method of claim 28, wherein cell survival of the cancer cell is decreased after contacting the cancer cell with at least one SUMOylation inhibitor.
30. The method of claim 28 or 29, wherein cell proliferation of the cancer cell is decreased after contacting the cancer cell with at least one SUMOylation inhibitor.
Citation Information
Patent Citations
Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer
US20210315911A1
Composition comprising streptonigrin and anticancer agent for preventing or treating brain tumor
WO2020159203A1
Cited By
Application of charantin IV in preparation of tumor treatment medicine
CN121731330A
